“I feel like I aged overnight.”

I hear some version of that sentence all the time.

Women tell me their skin suddenly feels thinner. Their jawline looks different. Fine lines seem more noticeable. Makeup doesn’t sit the way it used to. Their skin feels drier, more fragile, less resilient.

And almost every woman asks some version of the same question:

“Is this normal?”

The answer is yes.

But that doesn’t mean it’s something we should dismiss.

One of the biggest frustrations I hear from women is that they feel these changes happened all at once. They’re told it’s simply aging, but that explanation never feels quite complete.

Recently on unPAUSED, I sat down with board-certified plastic surgeon Dr. Tony Youn to talk about the science of skin aging, collagen, and menopause. During our conversation, he shared a statistic that immediately got my attention.

Women can lose up to 30% of their skin’s collagen during the first five years after menopause.

Thirty percent.

When you understand that number, many of the skin changes women notice during midlife suddenly make a lot more sense.

Why Does Skin Age Faster After Menopause?

One of the most important things I try to teach is that menopause is not simply a reproductive event.

It is a whole-body transition.

Estrogen receptors are found throughout the body, including the brain, bones, muscles, cardiovascular system, gastrointestinal tract, and skin.

Your skin is a hormone-responsive organ.

Throughout our reproductive years, estrogen helps support collagen production, skin thickness, hydration, elasticity, and wound healing.

When estrogen levels decline, the skin responds.

This is one reason so many women notice visible changes during perimenopause and menopause that seem to happen far more rapidly than they expected.

These changes are not imagined.

They are biological.

What Causes Collagen Loss During Menopause?

Both men and women lose collagen as they age.

According to Dr. Youn, that process starts surprisingly early, around our mid-twenties, at a rate of about 1% per year.

For women, menopause changes that trajectory.

Research suggests women can lose up to 30% of their collagen during the first five years after menopause, followed by continued accelerated loss afterward.

Collagen is the primary structural protein that gives skin its strength, firmness, and elasticity.

When collagen declines, the effects become visible.

You may notice:

• Thinner skin

• Increased dryness

• Fine lines and wrinkles

• Loss of firmness

• Reduced elasticity

• Easier bruising

• Slower healing

For some women, the changes are subtle.

For others, they feel dramatic.

Either way, understanding the role of estrogen helps explain why these changes often feel so sudden.

Can Hormone Therapy Help Protect Skin?

Because estrogen plays an important role in skin health, many women wonder whether hormone therapy can help.

The answer is nuanced.

Skin is one of many tissues that responds to estrogen, and some women notice improvements in skin quality after starting hormone therapy as part of their menopause treatment plan.

However, hormone therapy should never be prescribed solely for cosmetic reasons.

The decision to use hormone therapy should always be based on an individual’s symptoms, health history, risk factors, and goals, in partnership with a qualified healthcare professional.

What I think is important is understanding that skin changes during menopause are connected to hormonal changes. Once we understand the biology, the experience becomes a lot less mysterious.

Three Things Dr. Tony Youn Recommends for Healthier Skin After 40

After discussing the science, I asked Dr. Youn a simple question:

“If you could tell women over 40 to start doing three things tomorrow for their skin, what would they be?”

His answers were refreshingly practical.

1. Consider a Daily Hydrolyzed Collagen Supplement

Dr. Youn recommends taking a hydrolyzed collagen supplement daily.

The key is consistency.

No supplement can completely replace the effects of estrogen on collagen production, but some studies suggest collagen peptides may support skin hydration and elasticity when taken regularly.

Think of collagen supplementation as one tool in a larger strategy, not a magic solution.

2. Use Vitamin C in the Morning and a Retinoid at Night

If there are two skincare ingredients with substantial evidence behind them, these are near the top of the list.

Vitamin C acts as an antioxidant and helps support collagen production.

Retinoids help improve skin texture and stimulate cellular turnover.

For women who cannot tolerate retinoids, Dr. Youn recommends considering bakuchiol as an alternative.

Notice what is missing from this recommendation.

A complicated routine.

An expensive collection of products.

A twelve-step regimen.

Instead, he recommends focusing on a few evidence-based ingredients used consistently over time.

3. Consider Red Light Therapy

Red light therapy has gained significant attention in recent years, and Dr. Youn considers it one of the more promising at-home tools available for supporting skin health.

Like everything else on this list, consistency matters more than perfection.

Healthy skin is built through daily habits, not overnight transformations.

The One Skincare Mistake Dr. Tony Youn Wants Women to Stop Making

This was one of my favorite moments from our conversation.

I asked Dr. Youn what he wishes women would stop doing.

His answer?

Overcomplicating skincare.

He frequently sees patients who are using ten or twelve different products, only to end up with irritated, inflamed, unhappy skin.

Too many active ingredients.

Too many fragrances.

Too many products competing with one another.

Sometimes the answer is not adding more.

Sometimes the answer is simplifying.

Your skin barrier plays a critical role in skin health, and overwhelming it with products can often create more problems than it solves.

What Does a Simple Menopause Skincare Routine Look Like?

According to Dr. Youn, most women do not need an elaborate routine.

A simple foundation may be enough:

Morning

• Gentle cleanser

• Vitamin C serum

• Moisturizer

• Broad-spectrum sunscreen

Evening

• Gentle cleanser

• Retinoid or bakuchiol

• Moisturizer

Simple.

Consistent.

Evidence-based.

Menopause and Skin Aging: Common Questions Answered

Do collagen supplements work?

Dr. Youn recommends hydrolyzed collagen taken daily. While they are not a replacement for estrogen, some research suggests they may help support skin hydration and elasticity.

Is red light therapy worth it?

His answer was a definite yes.

Is face yoga effective?

Dr. Youn’s answer was no. Repetitive facial movements may actually contribute to wrinkle formation.

Should I microneedle at home?

He advises against at-home rollers because they can damage the skin and create complications.

Do drugstore anti-aging products work?

Absolutely. The key is choosing products with proven active ingredients rather than relying on marketing claims.

Is less filler sometimes better?

According to Dr. Youn, yes. He believes many faces today are being overfilled and that a more conservative approach often produces better results.

The Bottom Line

One of the first places women notice estrogen loss is in their skin.

The thinning.

The dryness.

The loss of elasticity.

The changes that can feel like they happened overnight.

These experiences are real, and they deserve more than a dismissive explanation.

Understanding the connection between estrogen and collagen helps explain why skin changes during menopause can feel so dramatic. It also reminds us that these changes are not a personal failure. They are part of a normal biological transition.

The good news is that there are things we can do.

Not because we are trying to look 25 forever.

But because understanding our biology allows us to care for our bodies more effectively through every stage of life.

And that has always been the goal.

Listen to the full episode of unPAUSED with Dr. Tony Youn here.

If you have sat in a doctor’s office in your forties or fifties and been told your labs are “normal,” then walked out still exhausted, still gaining weight you cannot explain, still waking at 3 a.m., still wondering whether you are losing your mind, this post is for you.

Standard menopausal workups, when they happen at all, usually stop at a CBC, a CMP, a basic lipid panel, and maybe a TSH. Those tests are useful. They check your kidneys, your liver, your blood counts, your cholesterol. But they were never designed to capture the cardiovascular, metabolic, bone, and hormonal shifts that define the menopause transition. Estrogen falls; ApoB rises; insulin sensitivity drops; bone turnover accelerates; ferritin sits in the basement after a decade of heavy periods. Almost none of that shows up on a standard panel.

This is the panel I order on every menopausal patient I see. Print it. Bring it to your next appointment. Keep your results, because the trend over years matters more than any single number.

A note before the list. “Normal” and “optimal” are not the same thing. A reference range tells you how your value compares to the statistical distribution of the lab’s testing population, which includes plenty of sick people. An optimal range is the target where the evidence suggests risk is lowest. Where there is strong society consensus on an optimal target, I will say so. Where the target is contested, or comes from preventive medicine practice rather than a society guideline, I will say that too. You deserve to know the difference.

1. Advanced Lipid Panel

Ask for: Total cholesterol, LDL, HDL, non-HDL cholesterol, triglycerides, ApoB (apolipoprotein B), Lp(a) (lipoprotein little a).

• LDL-C. Standard: <100 mg/dL. Optimal: <70 to 100 mg/dL (lower with risk factors).

• HDL-C. Standard: >50 mg/dL (women). Optimal: >60 mg/dL.

• Triglycerides. Standard: <150 mg/dL. Optimal: <100 mg/dL.

• Non-HDL cholesterol. Standard: <130 mg/dL. Optimal: <100 mg/dL (high risk: <85).

• ApoB. Standard: <130 mg/dL. Optimal: <80 to 90 mg/dL (high risk: <70).

• Lp(a). Standard and optimal: <30 mg/dL or <75 nmol/L.

Why it matters. Estrogen quiets cardiovascular disease in women for most of our lives. When it drops, that protection drops with it. LDL rises by an average of 10 to 15 percent across the menopause transition. Triglycerides rise. ApoB, which counts the number of atherogenic particles rather than just the cholesterol they carry, climbs.

ApoB is the better measure. Two women with identical LDL can have very different ApoB values, and the one with more particles carries more risk. The 2018 ACC/AHA cholesterol guidelines acknowledge ApoB as a risk-enhancing factor. The National Lipid Association calls it a more accurate marker of cardiovascular risk than LDL-C alone.

A note on Lp(a) that most lists get wrong. Lp(a) is mostly genetic, and for that reason it has been promoted as a once-in-a-lifetime test. That advice was written largely from data on men. In women, Lp(a) levels rise across the menopause transition. A 2022 systematic review and meta-analysis (Anagnostis et al., Maturitas) found that postmenopausal Lp(a) levels are on average 20 to 30 percent higher than premenopausal levels, and the Framingham Offspring data has shown the same direction. So my practice is to check Lp(a) at baseline in midlife and to recheck it after the menopause transition is complete. If yours was checked in your thirties and was “fine,” that is not the end of the conversation.

About one in five adults has an elevated Lp(a), and most do not know it. The European Atherosclerosis Society and the National Lipid Association both recommend universal Lp(a) screening at least once.

Sources: ACC/AHA 2018 Cholesterol Guidelines (Grundy et al., Circulation 2019); National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia (Jacobson et al., 2014); EAS Consensus Statement on Lp(a) (Kronenberg et al., 2022); Anagnostis et al., Maturitas 2022.

2. Blood Sugar and Insulin

Ask for: Fasting glucose, hemoglobin A1c, fasting insulin, HOMA-IR.

• Fasting glucose. Standard: <100 mg/dL (ADA). Optimal: 70 to 90 mg/dL.

• Hemoglobin A1c. Standard: <5.7% (ADA). Optimal: <5.4%.

• Fasting insulin. Standard: lab range varies (often up to 25 µIU/mL). Optimal: <7 to 10 µIU/mL.*

• HOMA-IR. Standard: <2.5. Optimal: <1.5.*

*The optimal cutoffs for fasting insulin and HOMA-IR are not set by the ADA or another major society. They reflect the preventive and metabolic medicine literature on insulin resistance as a continuous risk factor. There is no ADA-endorsed optimal fasting insulin value. I use these targets because the data showing insulin resistance precedes glucose dysregulation by years is overwhelming, but you should know they are practice-based, not society-endorsed.

Why it matters. Insulin resistance shows up years, sometimes a decade, before fasting glucose or A1c crosses into the diabetic range. Many women in perimenopause are running high insulin while their glucose looks fine. They feel the consequences: weight that will not budge, energy crashes, sugar cravings, a fatty liver no one explained.

The ADA defines prediabetes at A1c 5.7 to 6.4 percent. By the time you are there, insulin resistance has been working for years. Catching it early is the point.

3. Bone Health

Ask for: A baseline DEXA scan, 25-hydroxy vitamin D, calcium, and PTH (parathyroid hormone) if vitamin D is low.

• 25-OH Vitamin D. Standard: ≥20 ng/mL (IOM) or ≥30 ng/mL (Endocrine Society 2011). Optimal: 60 to 100 ng/mL.*

• Calcium. Standard: 8.5 to 10.2 mg/dL. Optimal: within range.

• PTH. Standard: 15 to 65 pg/mL. Optimal: within range; check if vitamin D is low.

• DEXA T-score. Normal: ≥ -1.0. Goal: ≥ -1.0.

*On the 60 to 100 target, be honest with yourself and your doctor about where this comes from. The 2011 Endocrine Society guideline endorsed levels above 30 ng/mL, with 40 to 60 ng/mL as the target for at-risk populations. The 2024 Endocrine Society guideline went the other direction and stepped back from recommending routine testing in healthy adults under 75. The IOM still considers 20 ng/mL sufficient at the population level. My target of 60 to 100 ng/mL is stricter than any of those positions and reflects preventive and menopause-medicine practice in women with bone, mood, immune, and cardiometabolic concerns. The upper bound matters: above 100 ng/mL, the evidence on benefit thins and the risk of hypercalcemia rises. Test, supplement intentionally, and retest, rather than guessing.

Why it matters. Postmenopausal bone loss is not slow. Trabecular bone, the kind in your hips and spine, is lost at roughly 2 percent per year for the first 4 to 5 years after the final menstrual period, then about 1 percent per year thereafter (data from SWAN and multiple longitudinal cohorts). That is 10 to 15 percent cumulative loss in the first decade after menopause, more in fast losers. You can be heading toward osteoporosis for years with no symptoms.

The USPSTF currently recommends DEXA at age 65, or earlier with risk factors. Waiting until 65 is too late for many women. If your doctor refuses a baseline scan, there is a script for that at the bottom of this post.

4. Thyroid

Ask for: TSH, free T4, free T3, TPO antibodies, thyroglobulin antibodies.

• TSH. Standard: 0.4 to 4.5 mIU/L. Optimal: 0.4 to 2.5 mIU/L.*

• Free T4. Standard: 0.8 to 1.8 ng/dL. Optimal: mid to upper half of range.

• Free T3. Standard: 2.3 to 4.2 pg/mL. Optimal: mid to upper half of range.

• TPO antibodies. Standard and optimal: <35 IU/mL.

• Thyroglobulin antibodies. Standard and optimal: <1.0 IU/mL.

*The 0.4 to 2.5 TSH target is endorsed by the American Association of Clinical Endocrinologists for symptomatic patients. Standard lab ranges run higher.

Why it matters. Hypothyroid symptoms (fatigue, brain fog, hair loss, weight gain, mood changes) are nearly indistinguishable from menopause symptoms. Autoimmune thyroid disease (Hashimoto’s) is five to ten times more common in women than men and frequently emerges in the perimenopausal years. TSH alone misses early Hashimoto’s. Antibodies catch it before the TSH moves. If you only run a TSH, your antibodies are positive, and your TSH is still in range, you can lose another five years before anyone notices.

5. Iron and Ferritin

Ask for: Ferritin. If ferritin is low, the full anemia panel: hemoglobin, hematocrit, total iron, TIBC, iron saturation.

• Ferritin. Standard: ≥30 ng/mL (current consensus cutoff for deficiency).* Optimal: 50 to 100+ ng/mL, depending on symptoms.

• Hemoglobin. Standard and goal: >12 g/dL.

• Iron saturation. Standard: 20 to 50%. Optimal: >25%.

*The old 15 ng/mL cutoff is outdated. The American Society of Hematology 2024 draft recommendations, the UK NICE guidelines, and a 2024 JAMA Network Open analysis all support ferritin ≤30 ng/mL as the cutoff for diagnosing iron deficiency in menstruating women. The WHO still lists 15 as a population-level threshold, but acknowledges it misses symptomatic patients. If any clinician is still using 15, ask them to look at the 2024 data.

Treatment goals depend on the symptom, not on hitting “normal.” This is where the standard reference range fails women most. Once your ferritin is below 50, and especially below 30, you can have real symptoms while your hemoglobin still looks “fine.” A CBC alone will miss it. The treatment target is not “above the cutoff,” it is symptom resolution.

• Hair loss and telogen effluvium: Most of the dermatology literature points to a target above 70 ng/mL for hair regrowth (some clinicians target 80 or above). Multiple observational studies, including a 2024 satisfaction study in Archives of Dermatological Research, show patients with baseline ferritin under 50 are more likely to remain dissatisfied with iron supplementation alone, and that hair benefit is greater when stores are pushed higher.

• Fatigue and brain fog: Symptom resolution often requires ferritin above 50 to 70, even when hemoglobin is normal. Iron deficiency without anemia is a real diagnosis with a growing evidence base.

• Restless legs syndrome: The 2024 American Academy of Sleep Medicine guideline recommends iron supplementation in adults with RLS if ferritin is ≤75 ng/mL, and recommends IV iron when ferritin is between 75 and 100. The brain-iron biology in RLS is different from systemic iron, which is why the target sits so much higher than the population cutoff.

Why it matters. A decade or more of heavy or irregular bleeding leaves a lot of women walking into menopause with depleted iron stores. Many of them have been told for years that their fatigue, shedding, or restless legs are “normal,” “stress,” or “just menopause,” when a simple ferritin test would have started a different conversation.

6. B12, Folate, and Methylation

Ask for: Vitamin B12, folate (serum or RBC), homocysteine.

• Vitamin B12. Standard: 200 to 900 pg/mL. Optimal: >500 pg/mL.*

• Folate. Standard: >3 ng/mL. Optimal: >7 ng/mL.

• Homocysteine. Standard: <15 µmol/L. Optimal: <9 µmol/L.*

*B12 deficiency symptoms can occur with values in the 200 to 400 pg/mL range, which is why preventive medicine practice targets above 500. Elevated homocysteine is associated with elevated cardiovascular and cognitive risk in observational data; the AHA acknowledges the association but does not endorse a specific optimal target.

Why it matters. B12 deficiency mimics every menopause complaint: fatigue, brain fog, low mood, neuropathy, memory problems. It is disproportionately common in women over 50, women on metformin, women on PPIs (omeprazole, pantoprazole, esomeprazole), and women on long-term oral contraceptives. Stomach acid drops with age, which further impairs B12 absorption. Reference ranges were set to catch frank anemia, not symptoms. If you have ever been told your B12 is “fine” at 280, that may not actually be fine.

7. Chronic Inflammation

Ask for: High-sensitivity C-reactive protein (hsCRP).

• hsCRP. Standard: <3 mg/L. Optimal: <1 mg/L (AHA low cardiovascular risk).

Why it matters. hsCRP is the cleanest general marker we have for systemic inflammation, and the AHA endorses it as a cardiovascular risk modifier. The 2003 AHA/CDC scientific statement (Pearson et al., Circulation) established the <1, 1 to 3, and ≥3 mg/L categories for low, average, and high cardiovascular risk. The JUPITER trial (Ridker et al., NEJM 2008) showed hsCRP independently predicts cardiac events. It also responds to lifestyle change: exercise, sleep, weight loss, nutrition. So you can use it to measure your work.

8. Hormones (situational, not routine)

Ask for, if the situation warrants it: estradiol by LC/MS, FSH, total and free testosterone, DHEA-S.

Why this is last, and why “optional.” In perimenopause, hormone levels swing wildly from day to day. A single estradiol or FSH measurement often tells you very little. The exceptions matter:

• You do not have periods to track, because of an IUD, ablation, or hysterectomy. FSH and estradiol can help locate you on the menopause timeline.

• You are under 45 and want to confirm premature or early menopause. Two FSH readings above 30 mIU/mL, taken weeks to months apart with low estradiol, is the picture.

• You are evaluating low libido, fatigue, or muscle loss, or considering testosterone therapy. Total and free testosterone establish a baseline.

These are not screening tests. They are situational. Asking for them when they are not going to change the plan wastes your time and gives your doctor a reason to dismiss the broader panel. Do not lead with hormones. Lead with the rest of this list.

What about the CBC and CMP?

You should still have them. They check your blood counts, kidney function, liver function, electrolytes, and basic metabolic status. They are essential and they are usually covered by insurance without argument. They are also not enough on their own, which is the entire point of this post.

What to Say When You’re Not Being Heard

The labs are the easy part. The harder part is getting them ordered, and getting your symptoms taken seriously when the results come back. Here are the scripts I give patients for the pushbacks I hear most often.

“You don’t need a bone scan yet, you’re not old enough.”

“The standard recommendation starts at 65, but bone loss accelerates during perimenopause. With my age and risk factors, I’d like a baseline now rather than wait for a fracture.”

“That’s just part of getting older.”

“I understand aging brings changes, but these symptoms are interfering with my daily life. I’d like to look at whether hormone shifts are contributing and what we can do about it.”

“Hormone therapy is too risky. I don’t recommend it.”

“I’ve read the current evidence. The 2013 JAMA reanalysis of the Women’s Health Initiative (Manson et al.) showed that for symptomatic women within ten years of menopause, without contraindications, the benefits of hormone therapy often outweigh the risks. I’d like to go through my personal risk profile rather than rule it out categorically.”

“You’re still having periods, this isn’t menopause.”

“Perimenopause symptoms begin years before periods stop. I’d like to discuss whether hormone fluctuations could be contributing to what I’m feeling.”

“This sounds like depression. Let’s try an antidepressant.”

“I’m open to addressing my mood, but I’d like to look first at whether hormone changes are contributing. Can we check the labs on this list and consider the bigger picture before adding a medication?”

“You probably just need to eat less and move more.”

“I’ve made lifestyle changes and I’m still struggling. The data on perimenopause and metabolic shifts, including insulin resistance, body composition, and visceral fat, is real. I’d like to look at the labs that capture that.”

“There’s nothing we can do, this will pass.”

“This transition lasts an average of 7 to 10 years. I’d like to use that time to protect my heart, brain, bones, and metabolism for the decades that follow.”

The bottom line

Menopause is not a five-year storm you white-knuckle through. It is the entry to the second half of your life, and the decisions you make in this window, about hormone therapy, about strength training, about labs you actually look at, set the trajectory for your bones, your brain, your heart, and your metabolic health for the next forty years.

Print this. Bring it. Track your results. And if your clinician will not have this conversation with you, find one who will. You can also download our Lab Checklist here.

Sources:

Lipids and cardiovascular: ACC/AHA 2018 Cholesterol Guidelines (Grundy et al., Circulation 2019); National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia (Jacobson et al., 2014); EAS Consensus Statement on Lp(a) (Kronenberg et al., European Heart Journal 2022); Anagnostis et al., Maturitas 2022, “The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis.”

Glucose and insulin: American Diabetes Association Standards of Care 2024.

Bone and vitamin D: IOM Dietary Reference Intakes for Calcium and Vitamin D (2011); Endocrine Society Vitamin D Clinical Practice Guideline (Holick et al., 2011); Endocrine Society Vitamin D for the Prevention of Disease Guideline (2024); USPSTF Osteoporosis Screening Recommendations (2018); Study of Women’s Health Across the Nation (SWAN).

Thyroid: American Association of Clinical Endocrinologists Thyroid Disease Guidelines; American Thyroid Association Hypothyroidism Guidelines.

Iron and ferritin: American Society of Hematology 2024 Draft Iron Deficiency Diagnosis Recommendations; NICE Clinical Knowledge Summary on Anaemia (Iron Deficiency); JAMA Network Open 2024 ferritin cutoff cohort analysis; WHO Serum Ferritin Concentrations for the Assessment of Iron Status (2020); American Academy of Sleep Medicine 2024 Treatment of RLS and PLMD Clinical Practice Guideline; Archives of Dermatological Research 2024 telogen effluvium ferritin satisfaction study; multiple dermatology reviews on ferritin and telogen effluvium.

B12 and homocysteine: Standard clinical chemistry references; AHA scientific statements on homocysteine and CVD risk.

Inflammation: AHA/CDC Scientific Statement on Markers of Inflammation and Cardiovascular Disease (Pearson et al., Circulation 2003); JUPITER trial (Ridker et al., NEJM 2008).

Menopause hormone therapy: Manson et al., JAMA 2013, “Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials.”

Optimal ranges flagged with an asterisk (fasting insulin, HOMA-IR, vitamin D 60 to 100, TSH ≤2.5, ferritin treatment targets above population cutoff, B12 >500, homocysteine <9) reflect preventive and menopause-medicine practice. Where they exceed current major society endorsement, that is flagged in the section text.

This is information, not individual medical advice. Your labs and your decisions belong to you and your clinician.

If you had told me ten years ago that I’d be combining GLP-1 medications with hormone therapy to help my patients manage menopause-driven metabolic disease, I would have raised an eyebrow.

When I trained, we were taught that weight was simple math. Calories in minus calories out. Obesity was framed as a failure of willpower. Menopause weight gain? A vanity complaint.

I carried those biases into practice. For years, I told women to eat less and move more. I truly believed that was enough.

Then I watched, again and again, as women in midlife did everything right. They tracked their calories, followed clean eating plans, stayed active. They still gained weight, especially around the midsection. Their labs (insulin, CRP, triglycerides) told a story of rising inflammation. They were high-stress, sleep-starved, and increasingly hopeless.

It was no longer defensible to blame them.

The deeper I dug, the clearer the picture became. Menopause is a metabolic tipping point. Hormone decline is not neutral. I had failed them. Medicine had failed them. The science is finally catching up.

Today I want to walk you through where we are now and where the science is going, on one of the most effective evidence-based strategies we have for menopause-related visceral fat and metabolic disease: the combination of GLP-1 medications and hormone therapy.

What Are GLP-1 Medications and How Do They Work?

GLP-1s (glucagon-like peptide-1 receptor agonists) mimic a hormone naturally produced in your gut. They tell your brain you are full, slow gastric emptying, and improve how your body handles insulin and blood sugar.

They have been around for decades. The first one, exenatide (Byetta), was inspired by exendin-4, a peptide found in the saliva of the Gila monster, a venomous desert lizard. Yes, really.

Modern agents like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound, which is technically a dual GLP-1/GIP agonist) are far more powerful. These are not just appetite suppressants. They reduce visceral fat, the dangerous inflammation-driving fat stored around your organs. Less visceral fat means lower inflammatory cytokines, better glucose control, improved lipid profiles, and reduced cardiometabolic risk.

Why Menopause Changes Weight, Fat Distribution, and Metabolism

During perimenopause and menopause, up to 70% of women gain weight. The real issue is where it goes. Estrogen loss drives fat deposition into the abdomen, transforming your body’s metabolic landscape.

Visceral fat is not just a cosmetic concern. It is a metabolic bomb. It increases the risk of:

• Type 2 diabetes

• MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NAFLD)

• Cardiovascular disease

The loss of estrogen also accelerates sarcopenia, the loss of lean muscle mass, which further slows metabolism and reduces energy expenditure.

This process is biological, not psychological.

Can Hormone Therapy and GLP-1 Medications Work Better Together?

Hormone therapy alone can attenuate visceral fat gain, improve insulin sensitivity, and support muscle mass. In my clinical practice, I began to see something remarkable. When I combined HT with GLP-1s, the results were significantly better than either alone.

A 2024 study in Menopause confirmed it. Postmenopausal women on semaglutide plus HT lost significantly more weight than those on semaglutide alone at every checkpoint: 3, 6, 9, and 12 months. They were also more likely to hit clinically meaningful milestones of 5%, 10%, even 15% weight loss, all while improving metabolic markers.

📚 Read the study (Hurtado et al., Menopause 2024): https://pubmed.ncbi.nlm.nih.gov/38446869/

A 2025 review by Ushanova and Demidova in Women’s Health and Reproduction reached the same conclusion. GLP-1 receptor agonists and dual GLP-1/GIP agonists are highly effective for weight loss and cardiometabolic improvement in menopausal women, though most data still come from non-menopause-specific obesity trials (STEP, SELECT, SURMOUNT).

HT likely enhances outcomes by improving sleep, mood, and motivation to stay active. All of which matter for long-term success. This is why I now consider combination therapy a frontline option for eligible patients.

Can GLP-1 Medications Affect Hormone Therapy Absorption?

Here is something that should be on every clinician’s radar and is not: GLP-1 medications and tirzepatide slow gastric emptying. That is part of how they work. But slowed gastric emptying can also reduce absorption of oral medications, including oral estradiol, oral progestogens, and oral contraceptives.

What this means in practice:

✅ If you are on a GLP-1 and oral estradiol, your absorption may be impaired. Talk to your clinician about switching to transdermal estrogen (patch, gel, or spray), which bypasses the gut entirely.

✅ If you are perimenopausal, still cycling, and using an oral contraceptive for pregnancy prevention, consider backup contraception while on a GLP-1.

✅ Oral micronized progesterone is the most commonly prescribed form for endometrial protection in women on systemic estrogen. The data on absorption interference is limited, but worth a conversation.

This is not a reason to avoid GLP-1s. It is a reason to think carefully about the route of administration of your hormone therapy. If your current clinician has not raised this with you, raise it with them.

📚 Ushanova & Demidova 2025 review: https://doi.org/10.31550/2712-8598-2025-4-8-zhzir

What Is Retatrutide and Is It Safe for Menopausal Women Yet?

Retatrutide (LY3437943) is the next-generation candidate in this class. It is a triple agonist, hitting GIP, GLP-1, and glucagon receptors simultaneously.

In a 2023 Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al.), retatrutide produced 22.8% to 24.2% mean weight loss at 48 weeks at the higher doses (8 to 12 mg). That exceeds current standard-of-care results.

A 2024 Phase 2 trial in Nature Medicine (Sanyal et al.) showed liver fat fell by 43% to 82% across the dose range in 24 weeks in patients with MASLD. Up to 79% to 86% of patients at higher doses achieved normal liver fat. A result like this, if it holds in Phase 3, reshapes how we treat fatty liver disease in midlife women.

Phase 3 trials under the TRIUMPH program are ongoing, testing retatrutide in obesity, type 2 diabetes, sleep apnea, knee osteoarthritis, and chronic kidney disease.

Here is what I need you to hear clearly:

Retatrutide is not FDA approved. There is no approved prescription pathway. The only legitimate access right now is through a clinical trial.

Compounded retatrutide is being sold by some telehealth platforms and peptide vendors. This is not legal under federal compounding rules, which require a drug to be either FDA approved or on the official FDA shortage list, neither of which applies to retatrutide. Sourced product has unverified purity, sterility, and dosing. I cannot recommend it. No responsible menopause clinician should be prescribing it. If a platform is selling it to you, that is a red flag about the rest of their clinical practice.

The science is exciting. The Phase 2 data is real. Wait for the Phase 3 readouts. Wait for FDA approval. Your impatience is not worth your health.

📚 References for the retatrutide data:

• Jastreboff et al., NEJM 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

• Sanyal et al., Nature Medicine 2024: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271400/

• Giblin et al., TRIUMPH rationale, Diabetes Obesity Metabolism 2025: https://doi.org/10.1111/dom.70209

How to Minimize Side Effects and Maximize Comfort

GLP-1s can cause nausea, constipation, and appetite suppression. Most side effects are mild and improve with time and careful dosing. Here is what I advise my patients:

✅ Hydration is non-negotiable. These drugs blunt thirst cues.

✅ Introduce fiber slowly. Gradual increases prevent bloating and constipation.

✅ Avoid carbonation. It worsens GI discomfort.

✅ Monitor your pace. Weight loss faster than 2 pounds per week raises risk for gallstones, muscle loss, and hair shedding.

💬 If you are uncomfortable, talk to your clinician. Side effect management is part of good care.

Protecting Muscle Is Non-Negotiable

Here is what too few clinicians are talking about. GLP-1s, by reducing appetite, can unintentionally reduce protein intake. That puts your muscle mass at risk.

Muscle is medicine. The more you have, the higher your resting metabolism, and the better your long-term outcomes for falls, fractures, cognition, glucose control, and longevity.

My recommendations:

🥩 Eat 1.3 to 1.6 grams of protein per kilogram of ideal body weight daily

💪 Resistance train 2 to 3 times per week

🥤 Use a high-quality whey protein (like in my menopause power shake)

📊 Track progress with DEXA or a smart body composition scale

It Is Not Willpower. It Is Biology in a Broken Environment.

Obesity is not a moral failure. It is a biological response to an obesogenic environment that did not exist 100 years ago.

In the 1950s, fewer than 10% of Americans had obesity. Today, over 40% do.

📚 CDC adult obesity facts: https://www.cdc.gov/obesity/adult-obesity-facts/index.html

Sedentary jobs. Ultra-processed food. Endocrine disruptors. Constant stress. Poor sleep. This is not about discipline. It is about fighting against a system that was never designed to support women’s health in midlife.

Final Thoughts: Rewriting the Narrative of Midlife Health

If you have been experiencing weight gain during menopause, it is not your fault. It is not a lack of willpower. And it is not too late.

You deserve a strategy grounded in science, supported by compassion, and tailored to your unique biology.

GLP-1 medications combined with hormone therapy offer a powerful, evidence-based approach. The next generation of these drugs, including retatrutide, is coming. Until then, what we have works, and it works well.

If your current clinician lacks knowledge about these options, find one who does. The Menopause Society maintains a directory of certified menopause practitioners.

✨ Protect your muscle

✨ Prioritize your protein

✨ Move your body

✨ Advocate for yourself

Knowledge is not fear mongering. Knowledge is freedom.

Menopause is inevitable. Suffering is not.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022. https://doi.org/10.1016/j.cmet.2022.07.013

2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology. 2021;20. https://doi.org/10.1186/s12933-021-01412-5

3. Giblin K, Kaplan L, Somers V, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2025;28:83-93. https://doi.org/10.1111/dom.70209

4. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. https://pubmed.ncbi.nlm.nih.gov/38446869/

5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972

6. Liu Q. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology. 2024;15. https://doi.org/10.3389/fendo.2024.1431292

7. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, Phase 2 trial conducted in the USA. The Lancet. 2023. https://doi.org/10.1016/S0140-6736(23)01053-X

8. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized Phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://doi.org/10.1038/s41591-024-03018-2

9. Tewari J, Qidwai K, Tewari A, et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2025;18:51-66. https://doi.org/10.1080/17512433.2025.2450254

10. Ushanova F, Demidova T. Menopause, obesity, and incretin therapy: new horizons in the fight for women’s metabolic health. Women’s Health and Reproduction. 2025. https://doi.org/10.31550/2712-8598-2025-4-8-zhzir

I want to share something important that has changed in cardiovascular medicine.

In 2024, the American Heart Association and American Stroke Association updated their guideline for primary prevention of stroke. For the first time, they formally named the things that happen to women’s bodies across the reproductive lifespan as stroke risk factors. Pregnancy complications. Premature and early menopause. Endometriosis. Certain hormone therapies.

In March 2026, the American College of Cardiology, the American Heart Association, and nine other professional organizations released an updated guideline for the management of dyslipidemia. It also formally names early menopause, preeclampsia, and gestational diabetes among the risk-enhancing factors that should refine cardiovascular risk assessment. It also expands recommendations for measuring lipoprotein(a) and apolipoprotein B, two markers that meaningfully sharpen the picture for women with these histories.

That is two major cardiovascular guidelines in less than two years, in alignment on the same point. A woman’s reproductive history is part of her cardiovascular risk profile. This is no longer one body’s position. This is the direction of the field.

A review just published in the Cleveland Clinic Journal of Medicine walks clinicians through what the 2024 stroke guideline means in practice. I read it carefully. I want you to know what is in it, and I want you to know how the 2026 lipid guideline reinforces and extends it, because this is information that should now be part of every conversation about your long-term health.

In plain terms: your gynecologic and obstetric history is cardiovascular data. The new guidelines now reflect that.

What pregnancy can tell you about your future heart and brain

For decades, gestational diabetes and hypertensive disorders of pregnancy were treated as temporary conditions that resolved at delivery. The science has moved.

Women who develop gestational diabetes have a tenfold higher lifetime risk of type 2 diabetes. They also have approximately double the risk of future cardiovascular disease, including ischemic stroke.

Preeclampsia affects 2 to 8% of pregnancies. Women with a history of preeclampsia have an 81% higher risk of stroke compared with those without preeclampsia. Preeclampsia is now recognized as an independent cardiovascular risk factor.

Other pregnancy-related events linked to elevated future stroke risk include recurrent pregnancy loss, preterm birth, placental abruption, small-for-gestational-age infant, and stillbirth.

In plain terms: if your pregnancy was complicated, that history matters for your cardiovascular care for the rest of your life. It belongs in your chart, and it belongs in the conversation.

Premature and early menopause

Menopause before age 40 is premature. Menopause before age 45 is early. About 5% of women experience early menopause naturally. Many more experience it surgically, after bilateral oophorectomy, or medically, after chemotherapy, ovarian suppression, or radiation.

Stroke risk in this population rises by 20 to 30%, regardless of cause. The earlier the menopause, the higher the risk. One pooled analysis of multiple prospective studies found a 57% increased stroke risk in women who went through natural menopause at 40 to 44, and a 69% increased risk in those who went through it at 35 to 39. Surgical menopause performed before age 48 carries similarly elevated risk for all stroke subtypes.

Here is the most actionable piece of this story.

In nearly all of these studies, the excess stroke risk was concentrated in women who did not receive hormone therapy. Estrogen replacement until at least age 45 mitigates much, though not all, of the excess risk. The international guidelines for premature ovarian insufficiency recommend physiologic estrogen replacement, with progestogen if the uterus is intact, until at least the average age of natural menopause unless there is a clear contraindication.

In plain terms: for women with premature or early menopause, hormone therapy until at least age 45 to 51 is the standard of care recognized by the AHA/ASA guideline and by the international POI guidelines. If you went through menopause early, this is a conversation worth having.

Endometriosis is a vascular condition

Endometriosis affects approximately 11% of reproductive-age women, and 30 to 40% of women who present with infertility. The vascular risk is now consistent across multiple international cohorts.

A nationwide Danish study of more than 60,000 women with endometriosis found a 15% increased risk of stroke. A UK cohort found a 19% increased risk. A US prospective study of laparoscopically confirmed endometriosis from the Nurses’ Health Study II found a 34% increased risk. A 2023 systematic review and meta-analysis confirmed the overall association across the literature.

The mechanisms are multifactorial. Chronic systemic inflammation from extrauterine endometrial lesions contributes to endothelial dysfunction. Hormonal treatments used to manage the disease modify vascular risk. Hysterectomy and oophorectomy performed for endometriosis lead to earlier surgical menopause, which independently raises cardiovascular risk. Women with endometriosis also have higher rates of adverse pregnancy outcomes, which add another layer of vascular risk.

Treatment selection matters. Combined hormonal contraceptives with ethinyl estradiol doses greater than 30 to 35 micrograms increase vascular risk in a dose-dependent way. Among the progestin-only options, depot medroxyprogesterone acetate injection is associated with increased stroke risk. Progestin-only pills containing drospirenone, norgestrel, or norethindrone, the etonogestrel implant, and the levonorgestrel intrauterine device are not.

In plain terms: endometriosis is not just a pain condition. It is also a vascular condition. Cardiovascular risk assessment belongs in the long-term care plan for these patients.

Polycystic Ovary Syndrome

PCOS, recently renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), is not formally listed by the AHA/ASA guideline as an independent stroke risk factor, but the data are substantial. A 2024 meta-analysis of more than 1 million women found 71% higher odds of stroke in women with PCOS. The 2023 International Evidence-Based PCOS guideline recommends cardiovascular risk assessment and counseling for these patients.

In plain terms: if you have PCOS, your cardiovascular risk profile is part of your long-term medical picture. Ask for the assessment.

The numbers, in one place

This is the summary table from the Cleveland Clinic Journal of Medicine review, showing the relative risk or hazard ratio of stroke for each sex-specific risk factor along with the recommended mitigation strategies. Bring this to your next appointment if it helps the conversation.

Recommendations to mitigate risk

For all categories below, comprehensive lifestyle modification applies: a heart-healthy diet, regular physical activity, smoking cessation, and maintaining a healthy weight.

• Adverse pregnancy outcomes: a detailed obstetric history should be part of every cardiovascular workup. Regular screening for hypertension, weight, smoking status, diabetes, and hyperlipidemia.

• Premature and early menopause: estrogen replacement therapy until the average age of natural menopause unless contraindicated. Lipid and diabetes screening at the time of premature menopause diagnosis. Annual screening for hypertension, weight, smoking status, and hyperlipidemia.

• Endometriosis: avoid treatments that induce premature or early menopause when possible. If using a combined hormonal contraceptive, consider one with ethinyl estradiol of 30 μg or less, or a progestin-only option. Regular cardiovascular risk screening.

• Hormonal contraceptives: in patients with elevated baseline stroke risk, consider a combined hormonal contraceptive with ethinyl estradiol of 35 μg or less, or a progestin-only option, or a nonhormonal contraceptive.

What now

If any of these risk factors are part of your story, here is how to translate the data into action.

Know your history and write it down

Make a one-page personal health summary that includes every pregnancy outcome (gestational diabetes, hypertensive disorders, preeclampsia, preterm birth, miscarriage, stillbirth, placental abruption, small-for-gestational-age infant), your age at menopause and how it occurred (natural, surgical, medical), any diagnosis of endometriosis or PCOS, and your current and past hormonal contraceptive or hormone therapy use. Bring this to every cardiovascular appointment. Most clinicians do not have time to dig through a full chart. Hand them the summary.

Get the right screening on the right schedule

Based on the AHA/ASA guideline and the recommendations in the table above, women with any of these risk factors should have:

• Annual blood pressure measurement, with home monitoring if any borderline or elevated readings

• A full lipid panel, including a one-time lipoprotein(a) and an apolipoprotein B

• Fasting glucose or hemoglobin A1c, especially if you had gestational diabetes

• Weight and waist circumference tracked over time

• Smoking status and cessation support if applicable

• For premature menopause: lipid and diabetes screening at the time of diagnosis

If you went through menopause before 45, ask about hormone therapy

Both the AHA/ASA stroke guideline and the international guidelines for premature ovarian insufficiency recommend estrogen replacement, with progestogen if the uterus is intact, until at least the average age of natural menopause unless a contraindication exists. If you have not had this conversation with your clinician, it is worth having now.

About Lp(a) and Apo B

Two lipid markers deserve special attention for women with any of these risk factors.

Lipoprotein(a), or Lp(a), is a genetically determined particle that drives atherosclerotic risk independently of LDL cholesterol. Lp(a) levels are largely set by your genes. The 2026 ACC/AHA Guideline on the Management of Dyslipidemia recommends measuring Lp(a) at least once in adulthood. Levels of 125 nmol/L or higher (or 50 mg/dL or higher) are associated with approximately a 1.4-fold increased risk of atherosclerotic cardiovascular disease, and levels of 250 nmol/L or higher (or 100 mg/dL or higher) are associated with approximately a 2-fold higher risk. The CCJM stroke review separately lists Lp(a) among the lipid markers that rise during late perimenopause and early postmenopause.

Apolipoprotein B, or Apo B, reflects the total number of atherogenic particles circulating in your blood. The 2026 ACC/AHA dyslipidemia guideline supports Apo B testing to refine risk assessment and guide therapy. It is particularly useful when triglycerides are elevated above 200 mg/dL, in patients with diabetes, or when LDL cholesterol is already low (under 70 mg/dL) and a standard lipid panel may underestimate residual risk.

If a standard lipid panel has been your only cardiovascular workup, ask whether adding Lp(a) and Apo B would refine your risk picture. Both are simple blood tests and do not require special preparation.

If you have endometriosis or PCOS, expand the care team

Cardiovascular risk assessment should be part of routine care, not something that waits for a problem. If your gynecologist is managing your condition without addressing long-term metabolic and vascular risk, ask for a referral to a primary care physician or preventive cardiologist who will.

If you are choosing or reviewing contraception

For women with elevated baseline stroke risk, the guidance now favors combined hormonal contraceptives with ethinyl estradiol of 35 micrograms or less, or a progestin-only option, or a nonhormonal option. Most modern combined pills are already low-dose, but it is worth confirming what you are taking and whether the formulation matches your risk profile.

The lifestyle pieces still matter

Across every risk category in this guideline, the same set of lifestyle modifications appear: a heart-healthy eating pattern, regular physical activity, smoking cessation, and maintaining a healthy weight. These are not soft recommendations. In a body already carrying additional vascular risk, lifestyle is not optional. It is one of the most powerful tools you have.

The takeaway

The 2024 AHA/ASA stroke guideline and the 2026 ACC/AHA dyslipidemia guideline mark a real shift. Reproductive history is now formally part of cardiovascular risk assessment for women, across two of the largest professional bodies in cardiovascular medicine. We know more than we did. We can do better. And you deserve care that reflects the most current evidence.

If any of these risk factors are part of your story, you now have information to bring to your next appointment. Guidelines move faster than clinical practice. Your clinician may not yet have integrated either of these updates into routine care, and you may need to share what you have learned. That is a reasonable, helpful thing to do, and a sign of an engaged patient.

This is education, not fear. Knowledge is freedom.

References

1. David PS, Nordhues H, Vegunta S. Sex-specific risk factors for stroke in women: Focus on the 2024 AHA/ASA guideline. Cleveland Clinic Journal of Medicine 2026; 93(5):297-303.

2. Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke 2024; 55(12):e344-e424.

3. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017; 10(2):e003497.

4. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019; 62(6):905-914.

5. Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35(8):1933-1943.

6. Farland LV, Degnan WJ 3rd, Bell ML, et al. Laparoscopically confirmed endometriosis and risk of incident stroke: a prospective cohort study. Stroke 2022; 53(10):3116-3122.

7. Havers-Borgersen E, Hartwell D, Ekelund C, et al. Endometriosis and long-term cardiovascular risk: a nationwide Danish study. Eur Heart J 2024; 45(44):4734-4743.

8. Okoth K, Wang J, Zemedikun D, et al. Risk of cardiovascular outcomes among women with endometriosis in the United Kingdom: a retrospective matched cohort study. BJOG 2021; 128(10):1598-1609.

9. Okoli U, Charoenngam N, Ponvilawan B, et al. Endometriosis and risk of cardiovascular disease: systematic review and meta-analysis. J Womens Health (Larchmt) 2023; 32(12):1328-1339.

10. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI, Panay N, Anderson RA, et al. Evidence-based guideline: premature ovarian insufficiency. Fertil Steril 2025; 123(2):221-236.

11. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026. doi:10.1161/CIR.0000000000001423

My mother is nearly ninety years old.

She lives now in a body that has been failing her for a long time. Sarcopenia has stripped the muscle from her arms and legs. Osteoporosis has hollowed her bones. She has suffered from multiple hip and pelvic fractures that have stolen her ability to walk and care for herself. Alzheimer’s has made every thought a struggle. Her short-term memory is gone. She is frail in every direction a body can be frail, and the woman inside that body is still there, but reaching her takes more than it used to.

This is the reality, and I want to start there because softening it would be a lie.

But I also want to tell you who she was.

She was a college athlete. She played basketball at a time when girls did not really play basketball, and she was good at it. She married. She became the mother of eight children. Eight. She fed them, raised them, kept the house, kept the peace, and somewhere in there, she also became a businesswoman. For nearly fifty years she and my father ran restaurants and an inn. Half a century of getting up before the sun, of cooking, of hosting, of building something and keeping it standing, of feeding strangers and turning them into regulars. She was brilliant. Sharp, capable, relentless, funny. The kind of woman who got things done because the alternative did not occur to her.

That is the woman I grew up watching. That is the woman in many ways I wanted to become.

And she has been disappearing for years.

Here is the part I think about most. My mother is walking the exact path her own mother walked before her. My grandmother spent the last decade of her life in profound frailty, with dementia that made her unrecognizable to herself and to the people who loved her. It was extraordinary, hard, and lasted far too long. My mother was her primary caretaker through all of it. She fed her, sat with her, watched her own mother lose ten years to a body and a brain that had abandoned her.

And then she walked the same road.

Not because she chose to. Not because she was careless. Because no one told her there was another way. Because the medical system that should have been protecting her bone density and her muscle mass and her brain in midlife had nothing to offer her.

Because the conversation about menopause in her generation, and frankly in mine until very recently, was about hot flashes and hormones and whether you could tolerate the discomfort. It was not about the next thirty years. It was not about whether she would still recognize her grandchildren at eighty-five. It was not about whether she would be able to stand up out of a chair without help.

My mother never slept without being sedated. Not in any year of her life I can remember. No one ever talked to her about circadian rhythm, about morning light, about the way estrogen shapes the architecture of a night’s sleep. They handed her a pill. She never knew what it felt like to fall asleep on her own, and we wonder why her brain did not protect itself.

And no one talked to her about community as medicine. My mother had enormous community in her working years. The restaurants and the inn made sure of that. But no one ever told her that the connections she built on her feet at sixty would need tending into her seventies and eighties, that the people a woman sees and eats with and calls shape her brain as powerfully as anything she lifts or swallows. The data on social connection and cognitive resilience is as strong as the data on exercise. Loneliness is a clinical risk factor. We treat it like a feeling. It is a physiology.

The system failed her. It failed her mother before her. And it is on track to fail my generation and my daughters’ generation if we do not change something.

I built Pause Strong because of this. A daughter watching her mother disappear and realizing that the same biology was sitting inside me, and inside my own daughters, waiting.

The science is not actually mysterious. Muscle is medicine. We lose it in midlife faster than we lose almost anything else, and that loss is the single biggest predictor of what the last decades of life will look like. Bone follows the same arc. Brain health is tangled into both, because muscle moves glucose, regulates inflammation, and protects cognition. Sleep is the third leg of that stool. Without it, muscle does not rebuild, glucose does not regulate, and the brain cannot clear the day’s metabolic waste. And the brain is built and protected, in part, by the people around it. The estrogen drop at menopause accelerates every one of these processes at once.

This is what should have been happening for my mother in her forties and fifties. Strength training. Protein. Resistance. Hormone therapy when appropriate. Sleep her own body produced. The recognition that the people around her were as much a part of her medicine as anything else. The kind of preventive care that treats the body as something to be built up rather than something to be managed as it breaks down.

It did not happen for her. It did not happen for her mother. And I was not going to let it not happen for me, or for my daughters, or for the women who walk into my office looking for a different ending than the one their mothers had.

Pause Strong did not come out of nowhere. It came out of years of work. The research that went into The New Menopause and The New Perimenopause changed how I think about midlife, and the women I have had the privilege of interviewing on unPAUSED kept changing it further. Dr. Vonda Wright on musculoskeletal aging and the bone and muscle window we cannot afford to miss. Dr. Louisa Nicola on the neuroscience of training the brain through the body. Dr. Lisa Mosconi on what estrogen does for the female brain and what its absence costs. Dr. Jocelyn Wittstein on orthopedics, hormones, and the joints and tendons that carry us into our last decades. Dr. Kerry Burnight, the gerontologist behind Joyspan, on purpose, connection, and joy as the medicine we are not measuring but that may shape the last decades of a life as powerfully as anything else. Each conversation made the same picture sharper. The interventions that protect a woman’s last thirty years are knowable, teachable, and largely absent from the care most women are offered.

Pause Strong is what happens when you take that picture seriously and build something a woman can actually use. It is a program built around the things we know protect women through the menopause transition and into the decades that follow. Strength. Bone. Brain. Sleep. Connection. The Six-Tool Toolkit that takes the science and turns it into something a woman can actually do, on a Tuesday morning, in her own house.

It is for the woman in her forties who is starting to feel something shift and does not want to wait until the bone scan comes back bad. It is for the woman in her fifties who has just been told her muscle mass is below the line and wants to know exactly what to do about it. It is for the woman in her sixties who refuses to accept that the next twenty years are a slow tapering off. It is for every woman who watched her mother decline and decided, somewhere in her bones, that she was not going to walk the same road.

I want to say something clearly.

The last thirty years of a woman’s life should not be a slow, painful negotiation with a body that is giving out. It should be strength. It should be resilience. It should be memories, the making of them and the keeping of them. It should be grandchildren on laps and trips taken and books read and meals cooked.

Too many women are losing that. Not for a few months at the very end. For years. For a decade. For the entire back half of a life that should have been theirs.

My mother has to fight for every thought now. The names of the restaurants come and go. The inn surfaces and fades. The fifty years of work, the people she fed, the rooms she kept ready, are still in her somewhere, but pulling them up takes more than her brain can give. She still knows me, most days. Some days it takes a while.

But I remember her. I remember the basketball player and the businesswoman and the mother of eight. I remember who she was before the system that failed her got to do its slow work.

And I am building, for my daughters and for myself and for every woman reading this, a different ending.

That is why Pause Strong exists.

The pillow. The shower drain. The brush. The part that suddenly looks wider in the morning mirror.

And then the moment that catches most of us by surprise. Scrolling through old photos. Stopping on one from five or ten years ago. Looking at the woman in the picture. Looking at yourself.

I used to have more hair.

That sentence is one of the quiet panics of midlife. It is also one of the most under-medicalized symptoms women bring to my office. If you are over 40 and your hair is changing, you are not imagining it. You are not being vain. The panic you feel is the most rational response to a real medical process happening on your own head, and you deserve a real medical answer.

Almost every woman I see who is worried about her hair has been told some version of “it’s just aging” or “everyone loses some hair.” Some have been handed a bottle of biotin and sent home. Almost none have had the workup they actually need.

I should know. For years, when a woman came into my office worried about her hair, I did what most of us were trained to do. I told her some thinning is normal at her age. I might have checked her thyroid if she pushed. I did not check her ferritin. I did not ask about how heavy her periods had been over the last decade. I did not ask about her diet, her medications, her stress, or her sleep. I might have suggested biotin or one of those collagen-and-keratin gummies they sell at the drugstore. And then I sent her home.

I have spent the back half of my career undoing that training, and hair loss is one of the topics where the cost of getting it wrong is the most personal. Hair sits at the intersection of how a woman feels and how she is seen. It is also one of the most reliable medical signals her body sends. And in mainstream women’s health, we have spent decades treating it like a vanity complaint instead of the diagnostic flag it actually is.

So let me tell you what I should have been telling those women.

What Causes Hair Loss in Women Over 40?

Hair loss in women over 40 is almost always more than one thing happening at the same time. The hair follicle is one of the most metabolically demanding structures in the human body. It responds to hormones, to inflammation, to nutritional status, and to stress. When several of these shift at once, which is exactly what happens around perimenopause and menopause, the follicle falters.

Here are the major drivers.

Female pattern hair loss (FPHL). Also called androgenetic alopecia. This is the most common cause of hair loss in women over 40, and its prevalence climbs steadily through midlife and peaks around and after menopause (Fabbrocini et al., 2018; Mysore et al., 2022). What you see is diffuse thinning across the crown, often with the frontal hairline preserved (Devjani et al., 2023; Fabbrocini et al., 2018; Mysore et al., 2022). What is happening underneath is follicle miniaturization. The follicle is still alive. It is just producing thinner, shorter, less pigmented hairs each cycle, until eventually it cannot produce a visible hair at all.

The biology behind FPHL is the changing balance between androgens and estrogens. As estrogen drops at menopause, the follicle becomes more sensitive to circulating androgens, and miniaturization accelerates (Gupta et al., 2025; Owecka et al., 2024).

In plain terms: the same hormonal shift that is changing your sleep, your bones, and your brain is also changing your hair.

Telogen effluvium (TE). This is the diffuse shed where you watch handfuls come out in the shower for weeks or months. TE is the follicle’s response to a system-wide stressor. Severe illness. Surgery. A medication change. A psychological trauma. A nutritional crash. Thyroid disease. The hormonal turbulence of perimenopause. Any of these can flip a large fraction of follicles into the resting phase at once, and 2 to 4 months later, the shed shows up (Phillips et al., 2017; Amatya & Joshi, 2021). The good news is that TE is usually reversible once the trigger is identified and corrected.

Iron deficiency. This is the cause we miss the most. In one series, nutrient deficiency was the top cause of female alopecia, and iron deficiency was found in roughly 70 percent of the women with hair loss (Lin et al., 2023). Most of these women had ferritin levels too low for normal hair cycling despite hemoglobin in the “normal” range (Amatya & Joshi, 2021; Lin et al., 2023).

This is the part I want every woman reading this to take with her. A normal CBC does not rule out iron deficiency hair loss. You need a ferritin.

Thyroid dysfunction. Hypothyroidism in particular is a common cause of TE and is associated with more severe shedding (Gupta et al., 2025; Dayel et al., 2024). It is one of the cheapest and easiest things to check, and one of the most commonly missed.

Other contributors. Vitamin D and other nutrient deficiencies, chronic illness, autoimmune disease, various medications, and significant psychological stress (Leavitt et al., 2025; Owecka et al., 2024; Dakkak et al., 2024; Lin et al., 2023).

There are also less common but important diagnoses worth keeping on the radar. Alopecia areata presents as discrete patches. Frontal fibrosing alopecia and central centrifugal cicatricial alopecia are scarring alopecias that can destroy the follicle permanently if not caught early (Leavitt et al., 2025; Dias et al., 2022; Phillips et al., 2017). If you see patches, scaling, redness, burning, or a hairline that is moving back, you need a dermatologist who specializes in hair, fast.

The Best Lab Tests and Medical Workup for Female Hair Loss

Before anyone tells you it is “just menopause,” you deserve a proper evaluation.

A reasonable starting workup includes a ferritin (aim for at least 40 to 60 ng/mL for hair growth, not just the lab’s “normal” of 15) (Amatya & Joshi, 2021; Lin et al., 2023), a TSH and thyroid panel (Gupta et al., 2025; Dayel et al., 2024), a vitamin D level, a basic metabolic panel, and a careful medication review. If there are signs of androgen excess, irregular cycles, adult acne, or hirsutism, hormonal labs may also be appropriate (Owecka et al., 2024; Fabbrocini et al., 2018).

A scalp exam by a clinician who actually knows what they are looking at matters too. The pattern of loss tells most of the story (Devjani et al., 2023; Fabbrocini et al., 2018; Mysore et al., 2022).

The Most Effective Treatments for Hair Loss in Women Over 40

The good news is that hair loss in women over 40 is one of the most treatable conditions in midlife medicine, if you have the right diagnosis and the right combination of interventions.

Topical minoxidil. This is the mainstay for female pattern hair loss, and it has decades of evidence behind it. 2 percent solution twice daily or 5 percent foam once daily are the standard regimens (Devjani et al., 2023; Fabbrocini et al., 2018; Mysore et al., 2022). It works by extending the growth phase of the follicle. It needs to be used consistently for at least 6 months before you can judge its effect, and it is a long-term commitment. If you stop, the gains reverse.

I used topical minoxidil for years myself, and it worked well. What got complicated was what I started calling the “hair math.” Topical minoxidil leaves residue. I do not wash my hair every day. I also color my hair, which meant the timing of application around color appointments became its own logistical project. Most women I know who have used topical for any meaningful length of time eventually run into some version of this. The medication works. The daily reality of using it on hair you are also trying to color, style, and not over-wash is more friction than people anticipate.

Low-dose oral minoxidil. This is what I switched to, and it has worked beautifully. It is also a real shift for women who cannot tolerate the topical version, or who simply want to be done dealing with a bottle every day. Low doses are effective and generally well-tolerated for FPHL (Randolph & Tosti, 2020; Pawlik et al., 2024; Deoghare & Sadick, 2023). It requires a prescription and a clinician who knows the protocol.

The honest trade-off, and the part you do not hear enough about: oral minoxidil can grow hair in places besides your scalp. I get a little extra growth on my face that needs some tending. It is manageable. It is also worth knowing about before you start, so you can decide whether the trade is worth it for you. For me, easy yes.

Oral finasteride and antiandrogens. Oral finasteride at 2.5 to 5 mg improves hair density in many postmenopausal women with FPHL (Kaiser et al., 2023; Starace et al., 2024; Mysore et al., 2022). Spironolactone and other antiandrogens are options, particularly when there are signs of androgen excess, with the regimen individualized by age and contraception needs (Ong et al., 2025; Owecka et al., 2024; Fabbrocini et al., 2018; Mysore et al., 2022; Deoghare & Sadick, 2023).

Correct the deficiencies. If your ferritin is low, repleting iron toward 40 to 60 ng/mL improves hair in iron deficiency alopecia and TE (Amatya & Joshi, 2021; Lin et al., 2023). If your thyroid is off, treat it (Gupta et al., 2025; Dayel et al., 2024). This piece is foundational. No topical or oral hair medication will compensate for an unaddressed nutritional or endocrine cause.

Procedural options. Platelet-rich plasma, microneedling, low-level laser therapy, and hair transplantation can each enhance or rescue hair density, often as add-ons to medical therapy (Rosenthal et al., 2024; Randolph & Tosti, 2020; Kaiser et al., 2023; Pawlik et al., 2024; Mysore et al., 2022; Deoghare & Sadick, 2023).

Natural agents. Saw palmetto, horsetail, pumpkin seed oil, and curcumin have early evidence as adjuncts targeting inflammation and 5-alpha-reductase, but the data is far weaker than for the prescription options, and excessive supplementation can cause problems of its own (Leavitt et al., 2025).

Combination therapy beats monotherapy. This is the most important treatment principle in this whole letter. Studies consistently show that combining minoxidil with an antiandrogen, with or without a procedure, outperforms any single treatment for FPHL (Kaiser et al., 2023; Mysore et al., 2022; Deoghare & Sadick, 2023). Hair loss in midlife is rarely a one-lever problem. It should not be a one-lever solution.

What Every Woman Should Understand About Midlife Hair Loss

Hair loss after 40 is not a vanity problem. It is a medical condition with real causes and real treatments, and the failure to take it seriously is one of the more reliable ways the medical system has dismissed women’s experience.

Your hair is telling you something. About your iron. About your thyroid. About your hormones. About the inflammatory and metabolic state of your whole body.

You deserve a workup, not a brush-off. You deserve a treatment plan, not just a bottle of biotin. You deserve a clinician who treats your hair the way they would treat any other tissue in your body. As something worth investigating, worth understanding, and worth fixing.

You can have your hair back. Or at least, you can have a fair fight for it.

That is a different ending than the one most women are offered. And it is the ending I am committed to giving every woman who walks into my office, every woman reading this, and every woman who comes after us.

I see you. I hear you. I am working on it.

References

Amatya, B., & Joshi, S. (2021). A Hospital Based Cross Sectional Study Evaluating Haemoglobin, Iron Profile and Thyroid Function Tests in Women with Telogen Effluvium, Female Pattern Hair Loss, and Alopecia Areata. Journal of Dermatology and Venereology, 19, 9-13. https://doi.org/10.3126/njdvl.v19i1.34551

Dakkak, M., Forde, K., & Lanney, H. (2024). Hair Loss: Diagnosis and Treatment. American Family Physician, 110(3), 243-250.

Dayel, S., Hussein, R., Atia, T., Abahussein, O., Yahya, R., & Elsayed, S. (2024). Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study. Medicine, 103. https://doi.org/10.1097/md.0000000000036803

Deoghare, S., & Sadick, N. (2023). Combination therapy in female pattern hair loss. Journal of Cosmetic and Laser Therapy, 25, 1-6. https://doi.org/10.1080/14764172.2023.2222942

Devjani, S., Ezemma, O., Kelley, K., Stratton, E., & Senna, M. (2023). Androgenetic Alopecia: Therapy Update. Drugs, 83, 701-715. https://doi.org/10.1007/s40265-023-01880-x

Dias, M., Rezende, H., & Trüeb, R. (2022). Hair loss in women. Journal of the Egyptian Women’s Dermatologic Society, 19, 73-80. https://doi.org/10.4103/jewd.jewd_53_21

Fabbrocini, G., Cantelli, M., Masarà, A., Annunziata, M., Marasca, C., & Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women’s Dermatology, 4, 203-211. https://doi.org/10.1016/j.ijwd.2018.05.001

Gupta, A., Economopoulos, V., Mann, A., Wang, T., & Mirmirani, P. (2025). Menopause and hair loss in women: Exploring the hormonal transition. Maturitas, 198, 108378. https://doi.org/10.1016/j.maturitas.2025.108378

Kaiser, M., Abdin, R., Gaumond, S., Issa, N., & Jimenez, J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology, 16, 1387-1406. https://doi.org/10.2147/ccid.s385861

Leavitt, A., Hawkins, S., Kindred, C., Frey, C., Gainers, M., Grekin, S., & Leavitt, M. (2025). Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. Journal of Drugs in Dermatology, 24(7), 659-662. https://doi.org/10.36849/jdd.8763

Lin, C., Chan, L., Wang, J., & Chang, C. (2023). Diagnosis and treatment of female alopecia: Focusing on the iron deficiency-related alopecia. Tzu-Chi Medical Journal, 35, 322-328. https://doi.org/10.4103/tcmj.tcmj_95_23

Mysore, V., Dhurat, R., Abraham, A., Thappa, D., Kumari, P., Sarkar, R., Damisetty, R., Khopkar, U., Mucchala, S., Rathod, R., & Gala, M. (2022). Optimal use of topical minoxidil in management of female pattern hair loss in India: an expert opinion. International Journal of Research in Dermatology. https://doi.org/10.18203/issn.2455-4529.intjresdermatol20220503

Ong, M., Avram, M., McMichael, A., Tosti, A., & Lipner, S. (2025). Anti-androgen therapy for the treatment of female pattern hair loss: a clinical review of current and emerging therapies. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.04.074

Owecka, B., Tomaszewska, A., Dobrzeniecki, K., & Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines, 12. https://doi.org/10.3390/biomedicines12030513

Pawlik, W., Nowotarska, A., Błaszczyński, G., Nojek, P., Zimonczyk, M., & Zawół, M. (2024). Hair loss therapies: a review and comparison of traditional and modern treatment methods. Journal of Education, Health and Sport. https://doi.org/10.12775/jehs.2024.75.56191

Phillips, T., Slomiany, W., & Allison, R. (2017). Hair Loss: Common Causes and Treatment. American Family Physician, 96(6), 371-378.

Randolph, M., & Tosti, A. (2020). Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.06.1009

Rosenthal, A., Conde, G., Greco, J., & Gharavi, N. (2024). Management of androgenic alopecia: a systematic review of the literature. Journal of Cosmetic and Laser Therapy, 26, 1-16. https://doi.org/10.1080/14764172.2024.2362126

Starace, M., Gupta, A., Bamimore, M., Talukder, M., Quadrelli, F., & Piraccini, B. (2024). The Comparative Effects of Monotherapy with Topical Minoxidil, Oral Finasteride, and Topical Finasteride in Postmenopausal Women with Pattern Hair Loss: A Retrospective Cohort Study. Skin Appendage Disorders, 10, 293-300. https://doi.org/10.1159/000538621

Here is what I want you to know. This topic was not in my OB-GYN training. It was not in my residency. It was not in continuing medical education. Throughout four years of medical school, four years of residency, and decades of clinical practice, no one ever connected mast cells to estrogen for me.

I learned about this from women on the internet who said their premenstrual dysphoric disorder (PMDD) improved while taking Allegra and Pepcid. I learned it from my menopause group chat, which includes about a hundred physicians who are slowly waking up to it. And last week, I learned a great deal more from Dr. Zachary Rubin, a double board-certified pediatrician and allergist-immunologist; New York Times bestselling author of All About Allergies; and one of the most trusted voices in immunology online.

Dr. Rubin has been quietly assembling these pieces in his own practice for years. While I was on book tour, the topic exploded across social media. The New York Times covered it. Women everywhere were trading stories about a humble over-the-counter combination changing their lives.

I asked him to walk me through what is real, what is speculative, and what is worth your attention.

This is the long version of that conversation. If you have been told it is “just anxiety” or “just perimenopause” or “just IBS,” this is for you.

Mast cells and histamine: what they actually do

Most of us learned about mast cells in the context of allergy. A bee sting. Pollen. Hives. End of story.

That story is incomplete.

Mast cells are part of your innate immune system. Your first line of defense. They live in your skin, your gut, your connective tissue, your lungs, and your brain. When they sense a threat, they degranulate, releasing a cocktail of mediators including histamine, tryptase, prostaglandins, and leukotrienes.

Here is the part that gets buried.

Histamine is not just an allergy molecule. It is a neurotransmitter. It regulates your sleep-wake cycle. It modulates your mood. It controls gastric acid secretion and aids digestion. It plays a role in vascular permeability and pain signaling.

When you understand that, you understand why the symptoms of mast cell dysregulation can look like everything and nothing. Brain fog. Fatigue. Itching. Bloating. A racing heart on standing. Anxiety in the luteal phase. Hives during ovulation. Migraines. Dizziness. The map sprawls.

Histamine is a jack of all trades. That is exactly what makes it so hard to pin down.

The connection no one taught us

This is the sentence I want every clinician reading this to underline.

Two hormones. Two opposing levers. Both fluctuating across the menstrual cycle, pregnancy, perimenopause, and the menopause transition.

In a regular ovulatory cycle, estrogen peaks around ovulation, drops, and then progesterone rises in the luteal phase. Many women with chronic hives, PMDD, migraine, endometriosis pain, or general histamine-coded symptoms describe a cyclical pattern. Worse before menstruation. Worse around ovulation. Worse on estrogen-containing contraception. Worse in the early follicular phase.

That pattern is not a coincidence. It is biology.

And then perimenopause enters the chat.

Perimenopause: the Zone of Chaos for histamine, too

If you have read my work, you know what I mean by the Zone of Chaos. The decade between roughly 35 and 55 when the ovaries stop running on a metronome and start running on a dice roll. Estrogen surges and crashes unpredictably. Progesterone falls earlier than estrogen does, often by years.

Now overlay the mast cell map onto that.

The brakes (progesterone) come off first. The accelerator (estrogen) starts spiking erratically and lingering longer than it should. The result is a system that has lost both its rhythm and its regulator.

For women who already had a histamine tilt, perimenopause can light it up. New-onset hives. Flushing that gets blamed on hot flashes alone. GI symptoms labeled IBS. Brain fog labeled stress. Anxiety labeled “midlife.” Mood symptoms that get a fresh SSRI without anyone asking what is happening underneath.

Roughly forty percent of women report new or worsened depression or anxiety in the menopause transition. We have been telling ourselves this is just hormones acting on the brain. What if part of this process involves hormones acting on the immune system, which in turn affects the brain?

We do not have the trials yet. We have the mechanism. And we have a lot of women.

H1 versus H2: the primer that explains the internet

The receptor confusion online has gotten loud. Let us slow this down.

There are four histamine receptors. Clinically we use medications targeting two of them.

H1 receptors are what classic allergy medications target. Benadryl (diphenhydramine), Claritin (loratadine), Zyrtec (cetirizine), Allegra (fexofenadine). These block H1 to reduce hives, itching, sneezing, runny nose, and swelling.

H2 receptors live in the gut. They drive gastric acid secretion. The most common H2 blocker is Pepcid (famotidine). You may have used it for heartburn.

But H2 receptors also live on mast cells. And on blood vessels.

For decades, allergists have known that for chronic urticaria, H1 alone is often not enough. They add Pepcid. The combination outperforms either drug alone. That has been in the standard chronic urticaria treatment algorithm for years.

What the internet has been doing, and what Dr. Rubin has been observing in his practice, is using that same H1 plus H2 combination for cyclical, hormone-modulated histamine symptoms. PMDD. Cyclical migraine. Endometriosis pain. Perimenopausal mood and sleep disruption.

Anecdotally, some women say it changed their lives. Some say nothing.

We do not have randomized controlled trials for any of these uses. Dr. Rubin was very explicit about this on the live, and I want to repeat it. There are no RCTs for H1 plus H2 in PMDD. None for endometriosis. None for perimenopause. None for menopause. None for pregnancy.

What we have is a clean mechanism, a long safety record for both medications, and a growing chorus of women saying it helped.

That is enough to take the question seriously. It is not enough to declare the drug a treatment.

MCAS: the three diagnostic pillars

Mast cell activation is a real condition. It is also overdiagnosed online and underdiagnosed in conventional clinics. To meet criteria, three things must be true.

One: multisystem symptoms. The classic presentation involves at least two organ systems.

• Skin: flushing, hives, itching, and dermatographism.

• Gut: bloating, pain, diarrhea, IBS-pattern symptoms.

• Cardiovascular: often overlapping with POTS, where heart rate climbs inappropriately on standing, with dizziness, faintness, and malaise.

• Plus brain fog and fatigue, which are not formal criteria, but show up in nearly every MCAS patient Dr. Rubin sees.

The overlap with perimenopause symptoms is enormous. He starts with MCAS and works outward. I start with menopause and work outward. We end up in the same room.

Two: laboratory evidence of mast cell activation. This is the hard part. The tests are flawed in different ways.

• Serum tryptase is the most reliable, but it has a short window. Tryptase rises during a mast cell event and lingers only four to six hours. Multiple draws are often needed, ideally captured during a flare.

• Urine leukotriene E4, prostaglandin D2, and 24-hour N-methylhistamine (collected on ice) are the standard urine tests. False negatives are common, particularly when the lab does not process the sample quickly. In Dr. Rubin’s community practice, urine prostaglandin D2 is the test that pops positive most often. The 24-hour N-methylhistamine collection, while standard in academic centers, is logistically miserable for patients.

A normal test once does not rule MCAS out. This is true of autoimmune disease as well. We may need to test repeatedly, especially during a flare, before the labs reflect what the patient is clearly experiencing.

Three: response to mast-cell-targeted treatment. Symptoms should meaningfully improve when treated with mast-cell-directed therapy. This is the criterion Dr. Rubin sees most often satisfied in his clinic.

If you have all three, you have MCAS. If you have one or two, you may still be a person whose symptoms are partly mast-cell-driven, but the formal label may not apply.

The treatment ladder

Here is the order of operations Dr. Rubin uses in real practice, simplified.

1. H1 plus H2 blockade. Daily Allegra or Zyrtec, daily Pepcid. Inexpensive, over the counter, well tolerated.

2. Cromolyn sodium. A mast cell stabilizer that is not absorbed systemically. It coats the GI tract and calms mast cells locally. Must be titrated up slowly because rapid escalation causes diarrhea (the very symptom you are trying to fix).

3. Montelukast (Singulair). A leukotriene receptor blocker. The FDA placed a black box warning on it for neuropsychiatric events including nightmares, mood swings, anxiety, depression, and suicidal ideation. Probable off-target effects on serotonin and dopamine receptors. Symptoms typically resolve when the drug is stopped. Use with caution.

4. Ketotifen, compounded. Another mast cell stabilizer. Sedating. Used selectively.

5. Omalizumab (Xolair). An injectable monoclonal antibody. Off-label for MCAS. Expensive. Variable response.

6. Remibrutinib (Rapsido). A newer oral BTK inhibitor approved for chronic urticaria. Stops mast cell activation upstream. Off-label use for broader MCAS is being explored.

This is not a list to self-prescribe from. It is a map so you know what is in the room when you walk into an allergist’s office.

What about quercetin, DAO, and low-histamine diets?

The honest answers.

Quercetin has antihistamine activity in the lab. The dose, timing, and human safety profile for histamine conditions are not well established. Supplements are not FDA regulated, so you cannot fully trust the label. If it works for you and you tolerate it, that is a data point. It is not yet evidence-based recommendation territory.

DAO (diamine oxidase) supplements. DAO is the enzyme that breaks histamine down. The theory is that supplementation may help histamine intolerance. The best randomized double-blind placebo-controlled trial we have on histamine intolerance gave subjects either histamine or placebo without telling them which. The two groups did not differ in symptoms. That does not close the question entirely, but it raises real questions about whether what we call “histamine intolerance” is really about ingested histamine at all. Whatever is happening in those patients may be something else.

Low-histamine diets. No standardization across published versions. No high-quality trials demonstrating benefit. Real risk of nutritional restriction and food anxiety. Methodical single-food elimination with reintroduction is reasonable. A blanket cut of “high-histamine foods” is not the answer.

You are not failing if these tools did not work for you. They were never well evidenced to begin with.

The HRT question

Some women appear to develop MCAS-like symptoms when they start hormone therapy. Some have a paradoxical reaction to oral micronized progesterone, feeling more anxious, more wired, or more groggy instead of calmer. Some develop urticaria-like reactions that track to the route or formulation.

The honest framing is that we do not yet know what is happening at a mechanistic level. Estrogen activates mast cells, so it is biologically plausible that some women on certain doses or routes are getting more mast cell activation than the dose was intended to produce. It is also plausible that what looks like an HRT reaction is something else entirely.

The clinical move when such an event happens is to switch formulations. Transdermal estradiol instead of oral. A different progesterone preparation. Some women who react strangely to oral micronized progesterone tolerate norethindrone-containing combination patches better, possibly because some of that progestin metabolism involves ethinyl estradiol exposure.

This is not a reason to avoid HRT. It is a reason to work with a clinician who will adjust until you find what fits.

What to do if you suspect histamine is part of your story

Start with a journal. Two cycles minimum.

Write down your symptoms by day. Track ovulation. Track menstruation. Note what you ate, what you took, what triggered or relieved anything. Look for patterns. The luteal flare. The ovulatory itch. The post-meal flush. The 3 a.m. wake-up after a glass of red wine.

Take that data to your physician.

Ask for a serum tryptase, ideally during a symptom flare. If your physician is not familiar with this work, bring printed materials. Bring Dr. Rubin’s book All About Allergies. He has a full chapter on MCAS with the lab list and treatment options.

A measured self-experiment is reasonable.

You can try over-the-counter daily Allegra plus Pepcid as a clinical trial with your physician’s input. One variable at a time. A defined trial period. A way to evaluate whether it actually helped. Do not stack ten supplements at once. Do not start cromolyn or montelukast without a physician.

If your symptoms are running your life, you need an allergist or immunologist or a knowledgeable internist.

There are not enough of them. Wait lists are long. In some Canadian provinces, the wait is two years. Some US patients drive hours to get to one. This is part of why women turn to social media. The system has not given them anywhere else to go.

We are building the ship while sailing it

Dr. Rubin said something I keep returning to. We are building the ship and riding it at the same time.

There are no RCTs yet. There are mechanisms, observations, and a population of women whose lived experience is data we should not dismiss. The job for those of us in clinical practice is to take women seriously when they tell us a treatment helped, monitor closely, and push for the trials we deserve.

We need an integrated neuroendocrine-immune model of women’s health. Estrogen does not just talk to bone and brain and heart. It talks to mast cells. It talks to T cells. It talks to autoreactive B cells. That is part of why so many autoimmune diseases unmask in the 30s and 40s when our hormones first start to fluctuate.

This is not a fringe topic. It is the next frontier.

· · ·

Thank you to Dr. Zachary Rubin (@rubin_allergy on Instagram) for the conversation that produced this post. The full conversation is available on our YouTube channel. His book All About Allergies contains a full chapter on MCAS, the diagnostic workup, and the treatment ladder. Dr. Rubin is coming on the unPAUSED podcast for a deeper dive soon.

Nothing in this post constitutes medical advice. Please work with a qualified clinician on any treatment decisions.

Post 10 of 10

One hundred percent of women who live long enough will go through menopause. And yet the medical system has treated this universal biological transition as a niche specialty concern.

We have spent nine posts walking through what menopause actually is, what it does to the body, and what can be done about it. We have covered the biology, the Big Six conditions, and the toolkit. We have looked at the evidence, named the gaps, and built the framework for informed decision-making.

Now we close with the question that underlies everything: how did we get here? How did a biological transition experienced by half the population become something most doctors are unprepared to manage, most women are uninformed about, and most of society treats as either invisible or inevitable?

The answer is a combination of research neglect, medical education failure, and a single misinterpreted study that set the field back by decades.

Why Menopause Research Has Lagged Behind

If you search PubMed for articles on pregnancy, you will find over 1,173,622 results. If you search for articles on menopause, you will find 99,768. Pregnancy lasts nine months. Menopause, including the perimenopause and postmenopause, spans decades. The research ratio is twelve to one in favor of the shorter event.

This is not an accident. This is a structural prioritization that reflects what medical research has historically valued: reproduction over longevity, fertility over quality of life, the beginning of biological potential over the management of its end.

The consequences of this gap are everywhere. We do not have robust data on menopause interventions in diverse populations. We do not have long-term studies comparing different hormone therapy regimens. We do not have adequate research on the interaction between menopause and chronic diseases like autoimmune conditions, which disproportionately affect women. We do not have good data on how race, ethnicity, socioeconomic status, and environmental exposures shape the menopausal experience.

We are flying blind on questions that affect billions of women, and we are doing it because for most of modern medical history, this simply was not considered important enough to fund, study, or prioritize.

Why Most Doctors Receive Little Menopause Training

In 2019, a survey of ob-gyn residency programs in the United States found that fewer than 7% of graduating residents felt adequately prepared to manage menopausal patients. Read that again. Fewer than 7% of the physicians most likely to see women in perimenopause and menopause felt ready to care for them.

This is not because residents are undertrained in general. It is because menopause education is not prioritized in medical school or residency curricula. Most physicians get a handful of lectures on menopause, if that. The focus is on reproductive endocrinology in the context of fertility, pregnancy, and contraception. Menopause is treated as an afterthought, a niche topic, something you can pick up later if you are interested.

The result is that the average primary care physician, the person most women will see when they start experiencing perimenopausal symptoms, has almost no formal training in recognizing, diagnosing, or treating this condition. They were not taught the STRAW staging system. They were not taught that perimenopause can start at 35. They were not taught that brain fog, joint pain, and new-onset anxiety can be hormonally driven. They were not taught how to prescribe hormone therapy safely and effectively.

So when a 42-year-old woman walks into their office complaining of sleep disruption, mood changes, and fatigue, and her labs come back “normal,” the physician reaches for what they do know: an antidepressant prescription, a referral to a therapist, or a recommendation to reduce stress and get more sleep.

The doctor is not being malicious. The doctor is being undertrained. And the woman pays the price.

How the WHI Study Changed Menopause Care for Decades

In 2002, the Women’s Health Initiative (WHI) published results from a randomized controlled trial of hormone replacement therapy in postmenopausal women. The study was stopped early due to an increased risk of breast cancer and cardiovascular events in the hormone therapy group. The headlines were immediate and catastrophic: “Hormone Therapy Causes Cancer.” “HRT More Dangerous Than Previously Thought.”

Within months, millions of women stopped hormone therapy. Prescriptions dropped by more than 80%. An entire generation of women was told that hormone therapy was dangerous, that the risks outweighed the benefits, and that menopause was something to endure without medical intervention.

The problem is that the headlines, and the clinical guidance that followed, misrepresented what the study actually found.

The WHI studied older postmenopausal women, with an average age of 63. These were women who were, on average, more than a decade past their final menstrual period. They were given a specific formulation of hormone therapy: oral conjugated equine estrogen (Premarin) combined with medroxyprogesterone acetate (Provera), which is not the same as the bioidentical estradiol and micronized progesterone that many women use today.

The increased breast cancer risk, when you actually look at the numbers, was small: an additional 8 cases per 10,000 women per year. The cardiovascular risk was concentrated in women who started hormone therapy many years after menopause. And critically, the study also found benefits: reduced fractures, reduced colorectal cancer, and likely reduced all-cause mortality in younger women who started hormones closer to menopause.

The reanalysis that came later, particularly the “timing hypothesis” data, showed that women who started hormone therapy during perimenopause or within ten years of their final menstrual period had reduced cardiovascular risk, not increased risk. The harm seen in the WHI was driven by starting hormones in older women, long after the window of benefit had closed.

But that nuance did not make it into the headlines. And an entire field was set back by the resulting panic.

We are still recovering from the WHI. We are still fighting the belief that hormone therapy is categorically dangerous. We are still having conversations with women who are suffering but terrified to try the one intervention most likely to help them, because they remember what they heard in 2002.

What Happens When Menopause Goes Untreated

Women live longer than men, but they spend approximately 20% of their lives in poorer health. This is not biology. This is neglect.

Women live longer than men, but the quality of those extra years is worse. Women spend more years living with disability, chronic disease, and functional limitation. They have higher rates of osteoporosis, sarcopenia, dementia, autoimmune disease, and frailty in later life.

This is not inevitable. This is not just “how women age.” This is what happens when a major hormonal transition is ignored, undertreated, and under-researched. This is what happens when we treat menopause as a cosmetic concern instead of a medical event with profound long-term consequences.

The research gap, the training gap, and the WHI aftermath have combined to create a system in which women are systematically under-supported during one of the most significant health transitions of their lives. And the cost, measured in suffering, in disability, in years lost to poor health, is enormous.

How Menopause Care Is Finally Improving

The good news is that the conversation is shifting, slowly but unmistakably.

Research funding for menopause is increasing. The National Institutes of Health has launched initiatives focused specifically on midlife women’s health. Pharmaceutical companies are investing in new treatments for vasomotor symptoms, genitourinary syndrome, and other menopause-related conditions. The data on the timing hypothesis has been disseminated widely enough that most menopause specialists now understand it, even if it has not yet reached primary care broadly.

Medical education is beginning to change. The Menopause Society has expanded its certification program. More residency programs are incorporating menopause-specific training. Younger physicians entering practice are more likely to have been exposed to updated guidelines than the generation before them.

Cultural awareness is exploding. Women are talking about menopause publicly in ways that were unthinkable even a decade ago. Books, podcasts, social media accounts, and advocacy organizations are breaking the silence. The shame is lifting. The demand for better care is growing.

This is progress. It is real, measurable, meaningful progress. But it is not enough, and it is not fast enough.

What Women and Doctors Need to Do Next

For the medical system:

Medical schools and residency programs need to make menopause education mandatory, comprehensive, and evidence-based. Every physician who will see women over the age of 35 should be able to recognize perimenopause, understand the STRAW staging system, know when to prescribe hormone therapy and when not to, and be prepared to manage the full spectrum of menopausal symptoms and long-term health risks.

We need more research. We need large, well-designed studies on hormone therapy formulations, timing, and duration. We need data on menopause in diverse populations. We need studies comparing lifestyle interventions, pharmacological interventions, and combination approaches. We need long-term outcome data. We need the same level of investment and rigor that we apply to every other major health transition.

Insurance companies need to cover menopause care. Hormone therapy, DEXA scans, menopause specialist consultations, and other evidence-based interventions should be accessible and affordable. This is not cosmetic medicine. This is preventive medicine with decades of downstream impact.

For patients:

Educate yourself. You have just finished a ten-post series on the biology and management of menopause. You now know more than most primary care physicians were taught in medical school. Use that knowledge. Ask informed questions. Advocate for yourself. Do not accept dismissal.

Find a menopause-trained provider. If your current doctor is not equipped to manage your care, find someone who is. The NAMS directory at menopause.org is a good starting point. You deserve a provider who understands the current evidence, who listens to you, and who treats you as a partner in your own care.

Share what you have learned. Talk to your friends, your sisters, your daughters, your colleagues. Break the silence. Normalize the conversation. The more women understand what is happening to their bodies, the more they can demand the care they deserve.

Vote with your voice and your wallet. Support organizations advocating for menopause research and education. Demand better from your elected officials. Push for policy changes that prioritize women’s health across the lifespan, not just during reproductive years.

Why Menopause Is a Public Health Issue

Menopause is not just a women’s health issue. It is a longevity issue. It is a public health issue. It is an economic issue. Women make up half the workforce, half the population, and the majority of caregivers. When women’s health suffers, everyone suffers.

Addressing menopause properly, comprehensively, and early has the potential to reduce healthcare costs, improve productivity, preserve independence in older women, and add quality years to life. The return on investment is enormous. The moral case is even clearer.

We cannot keep treating menopause as optional. We cannot keep underfunding the research, undertraining the physicians, and under-supporting the women. We cannot keep accepting that half the population will spend 20% of their lives in preventable poor health.

We can do better. We must do better.

Why I Wrote This Menopause Series

I have spent my career caring for women in this transition. I have seen the suffering caused by dismissal, the relief that comes with proper treatment, and the profound difference that knowledge and advocacy can make. I have seen women regain their lives, their sleep, their cognitive sharpness, and their sense of themselves after years of being told nothing was wrong.

I wrote this series because I believe that knowledge is power, that information is medicine, and that women deserve both. I wrote it because I am tired of watching women suffer needlessly. I am tired of seeing brilliant, capable, strong women gaslit into believing their symptoms are imaginary or their fault. I am tired of a medical system that has failed this population for far too long.

If you have read all ten posts in this series, you now have the foundation to navigate your own menopausal transition with clarity, agency, and informed confidence. You know what is happening in your body. You know what the risks are. You know what the interventions are. You know what questions to ask and what standards to demand.

That knowledge will not fix everything. It will not make the transition painless or simple. But it will give you the power to make informed decisions, to advocate effectively, and to build the healthspan you want for the decades ahead.

And that, ultimately, is the point of all of this.

What to Do If You’re in Perimenopause or Menopause

If you are a woman in perimenopause or menopause:

• Find a Menopause Society-certified menopause practitioner

• Schedule a DEXA scan if you have not had one

• Start resistance training if you are not already

• Track your protein and fiber intake

• Write down your symptoms and bring them to your next appointment

• Share this series with other women who need it

If you are a clinician:

• Get Menopause Society certified if you see perimenopausal or menopausal patients

• Consider the excellent courses from Dr. Heather Hirsch or Dr. Rachel Rubin

• Update your knowledge on the timing hypothesis and current MHT guidelines

• Screen women in their 40s for bone density and metabolic risk

• Listen to your patients without dismissal

• Advocate for better menopause education in your institution

If you care about women’s health:

• Demand more research funding for menopause

• Support organizations advocating for menopause education and access to care

• Push for insurance coverage of evidence-based menopause interventions

• Normalize the conversation

• Break the silence

This is not the end. This is the beginning.

You are not broken. You are not aging out of relevance. You are navigating a profound biological transition in a medical system that was not built to support you.

But you are not alone. You are informed. You are capable. And you deserve care.

The second half of your life can be the best half. Build it deliberately. Build it informed. Build it well.

Thank you for reading this series.

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

For more information, visit:
The Menopause Society: menopause.org
The Pause Life: thepauselife.com

What You Really Need to Know About Menopause

Post 9 of 10

We have spent the last several posts walking through the biology of menopause, the Big Six conditions that estrogen loss drives or accelerates, and the evidence for what matters. We have looked at bone loss, muscle loss, insulin resistance, visceral fat accumulation, dementia risk, and cardiovascular disease. We have named the gaps in medical training, the dismissals women face, and the structural failures that have left so many women unsupported during one of the most significant transitions of their lives.

Now we build the plan.

This post is the synthesis. It is where we take everything we know and turn it into something actionable, practical, and sustainable. Not a prescription, because your body and your life are not the same as anyone else’s. But a framework. A toolkit you can adapt to your own circumstances, your own preferences, your own risk profile, and your own goals.

The evidence-based interventions that can reduce your symptom burden, lower your long-term disease risk, and support your quality of life through the menopausal transition and beyond.

This is not about perfection. It is about progress. It is about doing what you can, with what you have, where you are.

Nutrition: The Midlife Health Foundation

If you take nothing else from this series, take this: nutrition is not about restriction, punishment, or achieving some idealized body. It is about giving your body what it needs to function well during a metabolically demanding transition.

Nutrition Essentials

• Anti-inflammatory eating pattern: Prioritize whole foods, vegetables, fruits, healthy fats (olive oil, avocado, nuts, fatty fish), and minimize processed foods, refined carbohydrates, and industrial seed oils. This is not a named diet. It is a pattern.

• Protein: 1.3 to 1.6 grams per kilogram of ideal body weight per day. This is significantly more than most women are eating. For a 150-pound (68 kg) woman, this means roughly 90 to 110 grams of protein daily. Protein supports muscle preservation, satiety, and metabolic health. Data from the Women’s Health Initiative found that women with protein intake at 1.6 g/kg had the lowest risk of frailty. But protein alone is not enough. You must combine adequate protein with resistance training for it to preserve muscle mass.

• Fiber: greater than 25 grams per day, ideally 35+ grams. Fiber supports gut health, improves insulin sensitivity, lowers cholesterol, and reduces cardiovascular risk. Most women are getting less than half of this amount.

• Added sugars: less than 25 grams per day. This is not total carbohydrates. This is added sugars. One can of soda contains approximately 39 grams. A flavored yogurt can contain 20 grams. Check labels. The impact on insulin sensitivity is real.

• Track your intake, at least initially. Use a nutrition tracking app like Cronometer. You cannot manage what you do not measure. Most women are shocked when they see how little protein and fiber they are actually consuming, and how much added sugar has crept in.

This is not a short-term intervention. This is how you eat now. Not forever at 100% adherence, because life is not a controlled study. But as your baseline, your default, the thing you return to when you have drifted.

Movement: The Non-Negotiable Investment

If nutrition is the foundation, movement is the structure. You cannot supplement your way out of a sedentary life. You cannot medicate your way to strong bones and preserved muscle. You have to move, and you have to move in specific ways.

Movement Essentials

• Stretch every day. Flexibility and mobility decline with age and estrogen loss. Daily stretching maintains range of motion, reduces injury risk, and supports joint health. Ten minutes counts.

• Practice balance training every day. Falls are the leading cause of injury-related death in older women. Balance training reduces fall risk. Stand on one foot while brushing your teeth. Walk heel to toe. Practice standing from a seated position without using your hands. This is geroprotective.

• Resistance training with progressive load, three days per week. This is the most important item on this list. Lift weights. Use resistance bands. Do bodyweight exercises. Work against gravity and resistance. Structure it as push day, pull day, leg day if that helps you stay consistent. The key is progressive load, meaning over time you increase the weight, the reps, or the difficulty. This is what preserves bone density, builds muscle mass, improves insulin sensitivity, and protects you against sarcopenia and frailty. If you do nothing else, do this.

• Cardiovascular training: 150 minutes per week in zone 2. Zone 2 is the intensity where you can still hold a conversation but you are working. This improves cardiovascular health, metabolic efficiency, and VO2 max, which is one of the strongest predictors of longevity. Walk briskly, cycle, swim, hike. Just move consistently at moderate intensity.

If you are new to resistance training, hire a trainer for even a few sessions to learn proper form. If cost is a barrier, there are excellent free resources online (look for certified trainers with experience working with midlife women). If you have never lifted weights in your life, start now. It is not too late. Muscle responds to resistance training at any age.

Stress Reduction and Sleep: The Invisible Multipliers

Chronic stress and poor sleep will undermine everything else you are doing. They accelerate insulin resistance, worsen inflammation, impair cognitive function, disrupt hormonal balance, and increase your risk of cardiovascular disease. You cannot optimize your health while running on four hours of sleep and chronic cortisol elevation.

Stress Reduction

• Sunlight exposure, especially in the morning. Viewing sunlight increases serotonin production in the brain, the neurotransmitter linked to mood and well-being. It also supports circadian rhythm regulation, which improves sleep.

• Grounding (earthing). Getting your bare hands or feet on natural surfaces like grass or soil has been shown to lower stress hormones and reduce markers of chronic inflammation. The data is preliminary but intriguing, and the intervention is free.

• Find what works for you. Meditation, breathwork, yoga, walking in nature, time with friends, creative pursuits, therapy. Stress reduction is not one-size-fits-all. The goal is to have tools you can use when stress spikes, and practices that lower your baseline stress over time.

Sleep Optimization

• Use a wearable sleep tracker. You cannot improve what you do not track. A device like an Oura ring, Whoop band, or Apple Watch can show you patterns you would not otherwise see. How does alcohol affect your deep sleep? What happens when you eat late? When you go to bed at 10 pm versus midnight? The data is clarifying.

• Practice good sleep hygiene. Cool, dark, quiet room. Consistent sleep and wake times. No screens for an hour before bed. Limit caffeine after noon. Limit alcohol (it fragments sleep even if it helps you fall asleep initially). Address the vasomotor symptoms, anxiety, or joint pain that may be waking you up at night. Sleep is not a luxury. It is a biological requirement.

If you are doing everything right with nutrition and movement but your sleep is terrible and your stress is unmanaged, you will not see the results you are capable of. These are not things you address after you fix everything else. These are part of the foundation.

Pharmacology and Supplementation: Filling the Gaps

Lifestyle interventions are the foundation, but they are not always sufficient. Some women will need pharmacology. Some will benefit from targeted supplementation. This is not a sign of weakness or failure. This is medicine.

Menopause Hormone Therapy (MHT)

Consider MHT if the benefits outweigh the risks for your individual situation. MHT is the most effective treatment for vasomotor symptoms (hot flashes, night sweats). It improves sleep, mood, brain fog, joint pain, and sexual function in many women. It reduces bone loss, improves insulin sensitivity, and may reduce cardiovascular risk when started during the perimenopausal window or within ten years of the final menstrual period (the timing hypothesis). It preserves muscle mass better than lifestyle interventions alone.

MHT is not appropriate for everyone. Women with a history of breast cancer, blood clots, stroke, or certain other conditions may not be candidates. But for the majority of healthy women in perimenopause or early postmenopause, the benefits outweigh the risks. This is a conversation to have with a menopause-trained provider who understands the current evidence, not outdated guidelines from the Women’s Health Initiative misinterpretation.

If you are a candidate for MHT and you are suffering, this is not vanity. This is symptom relief and long-term risk reduction. You are allowed to feel better.

Other Pharmacology

Depending on your risk profile, other medications may be appropriate:

• Bisphosphonates or other bone-protective medications if you have osteoporosis or high fracture risk

• Metformin for insulin resistance or prediabetes

• Statins for cardiovascular risk reduction in women with established disease or very high risk (though the primary prevention data in women is weaker than most people realize)

• Antidepressants or other mood stabilizers if depression or anxiety is present and not responsive to hormonal or lifestyle interventions

These are individual decisions based on your labs, your symptoms, your history, and your goals. Work with a provider who treats you as a partner in decision-making, not a passive recipient of prescriptions.

Supplementation (if not obtainable from food)

• Fiber supplement to reach a total daily intake of 25+ grams if you cannot get there from food alone

• Omega-3 fatty acids: 2 grams per day. Supports cardiovascular health, reduces inflammation, and may support brain health. Choose a high-quality fish oil or algae-based supplement.

• Vitamin D: 4,000 IU per day with vitamin K2. Most women are deficient. Vitamin D supports bone health, immune function, and mood. Vitamin K2 helps direct calcium to bones rather than arteries.

• Creatine: 5 grams per day. Supports muscle mass, strength, and potentially cognitive function. The data in aging women is promising.

• Optional: Turmeric (curcumin), berberine, vitamin E. These may have benefits for inflammation, insulin sensitivity, and other metabolic markers, but the evidence is less robust. Discuss with your provider based on your specific risk factors.

Supplements are not magic. They fill gaps. They do not replace a terrible diet, a sedentary lifestyle, or inadequate sleep. Use them strategically, not indiscriminately.

Personalized Care: Your Plan, Not a Template

The New Menopause advocates for personalized treatment plans that consider your individual needs, preferences, symptoms, risk factors, and health goals. This might include hormone replacement therapy, alternative therapies, lifestyle changes, or a combination. What works for your friend, your sister, or the woman you follow on Instagram may not be what works for you. And that is okay.

There is no single right way to navigate menopause. There is only your way, informed by evidence, guided by a provider who listens, and adapted as you learn what your body responds to.

Some women will use MHT. Some will not. Some will need aggressive bone protection. Others will not. Some will thrive on a plant-based diet. Others will need more animal protein. Some will love lifting weights. Others will prefer swimming or hiking. The toolkit is the same. The way you use it is yours.

Empowerment and Education: You Are the Agent of Your Own Midlife Health

Women are encouraged to educate themselves about the changes happening in their bodies, to take an active role in their health care decisions, and to advocate for what they need. The emphasis is on empowerment, self-care, and informed choices.

You are reading this series because you want to understand what is happening to you. That act of seeking information is itself powerful. You are not waiting for permission. You are not waiting for your doctor to bring it up. You are educating yourself so that when you walk into that appointment, you can ask informed questions, push back on dismissals, and demand the care you deserve.

This is not about becoming your own doctor. It is about becoming an informed participant in your own care.

When you understand the biology, you can evaluate treatment options. When you understand the evidence, you can ask better questions. When you understand what is normal and what is not, you can advocate for yourself without apologizing.

Knowledge is not just power. Knowledge is agency. And agency changes everything.

What Can Actually Change

Let me be very clear about what the evidence tells us is possible when women implement these interventions comprehensively and consistently.

We can decrease all-cause mortality, cancer mortality, cardiovascular mortality, metabolic syndrome, osteoporotic fracture, dementia, and frailty.

We can increase quality of life and healthspan.

These are not small effects. These are not marginal gains. This is the difference between a woman in her 70s who is vibrant, independent, and physically capable, and a woman in her 70s who is frail, dependent, and limited by disease. The choices you make now, in perimenopause and early postmenopause, set that trajectory.

You cannot control everything. Genetics matter. Luck matters. But you can influence far more than you think. The question is whether you will.

Where to Start

If you are reading this and feeling overwhelmed, start small. You do not have to implement everything at once. Pick one thing. Do it consistently. Then add the next thing.

Your First Steps

1. Track your protein intake for three days. Use Cronometer or a similar app. See where you actually are. Most women are shocked to discover they are eating half of what they need.

2. Schedule a DEXA scan. Know your bone density. Know your body composition. Baseline data matters.

3. Start resistance training this week. Even if it is just bodyweight squats, pushups against a wall, and planks. Start. Consistency beats perfection.

4. Find a menopause-trained provider. Use the North American Menopause Society (NAMS) directory at menopause.org to find a certified practitioner near you. If your current doctor is dismissive, find a different one. You deserve better.

5. Write down your symptoms. All of them. Bring the list to your next appointment. Do not minimize. Do not apologize. Advocate for yourself.

6. Join a community. Find other women going through this. Online, in person, wherever. Isolation makes everything harder. Community makes everything more bearable.

You do not have to do this perfectly. You just have to do it. Progress, not perfection. Consistency, not intensity. Small actions, repeated over time, compound into meaningful change.

The Honest Truth

Some days you will not want to lift weights. Some days you will eat the entire pint of ice cream. Some days you will skip the vegetables and the fiber and the protein tracking and just survive. That is fine. That is human. That is life.

The goal is not to be perfect. The goal is to have a default you return to. A baseline that supports your health even when you are not thinking about it. Habits that are strong enough to bend without breaking.

This toolkit is not a prison. It is a framework. Use what works. Adapt what does not. Be kind to yourself when you fall short. Get back up. Keep going.

You are building a body and a life that can carry you through the next 30, 40, 50 years. That is worth the effort.

If you are ready for more support, the Menopause Empowerment Guide walks you through exactly how to build that foundation.

Your Personal Checklist

1. Am I eating 1.3–1.6g protein per kg of ideal body weight daily?

2. Am I getting 25+ grams of fiber per day?

3. Am I doing resistance training 3x per week with progressive load?

4. Am I getting 150 minutes of zone 2 cardio per week?

5. Am I prioritizing sleep and managing stress?

6. Have I had a DEXA scan to assess bone density?

7. Have I discussed MHT with a menopause-trained provider?

8. Do I have a plan, not just good intentions?

Coming in Post 10:

What Your Doctor Wasn’t Taught
The education gap, the WHI aftermath, where the field is heading, and the call to action for both patients and clinicians. The final post in the series.

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

Post 7 of 10

She was 47 and finding herself mid-sentence with no idea what she had been about to say. She forgot words she had known for decades. She walked into rooms and stood there, confused about why. She had always been sharp. Her colleagues knew her for her recall. Now she was quietly terrified.

Her doctor told her it was stress. Or sleep deprivation. Or anxiety. All of those were probably contributing. But nobody mentioned the thing that was almost certainly the primary driver: her brain was in the middle of a profound hormonal transition, and the estrogen it had relied on for decades to regulate memory, cognition, energy metabolism, and neuroprotection was rapidly declining.

Brain fog is one of the most commonly reported and most consistently dismissed symptoms of perimenopause. Women are told it is stress, aging, distraction, or depression. It is often something else entirely. And the stakes of getting this wrong extend far beyond inconvenience, because what happens to the female brain during the menopausal transition may have lasting consequences for dementia risk decades later.

The Statistic That Demands Attention

The connection between early estrogen loss and increased dementia risk is one of the most important and least discussed findings in women’s brain health research.

20% Early menopause or premature ovarian insufficiency (POI) increases dementia risk by up to 20% compared to women who reach menopause at the average age.

This is a large effect. And its mechanism is direct: the earlier estrogen is lost, the longer the brain operates without its neuroprotective support, and the greater the cumulative neurological consequence.

Alzheimer’s disease affects women at nearly twice the rate of men. For a long time this was attributed to the fact that women live longer, and longevity is itself a risk factor. But the data increasingly suggests that biology is doing more work here than lifespan alone. The female brain is built in relationship with estrogen. Its loss is not a neutral event.

What Estrogen Does Inside Your Brain

Estrogen receptors are distributed throughout the brain, concentrated in regions with the highest relevance to cognition, memory, mood, and neuroprotection. Estrogen is not a peripheral actor in brain health. It is a central one.

Memory Formation

Estrogen supports hippocampal neurogenesis and synaptic plasticity, the physical basis of learning and memory consolidation.

Glucose Metabolism

Estrogen supports the brain’s preferred fuel source. Without it, cerebral glucose uptake declines, creating an energy deficit that underlies many cognitive symptoms.

Neurotransmitter Regulation

Estrogen modulates serotonin, dopamine, acetylcholine, and GABA systems, which regulate mood, focus, motivation, and sleep architecture.

Neuroprotection

Estrogen reduces amyloid-beta production and promotes its clearance, suppresses neuroinflammation, and supports cerebrovascular health, all directly relevant to Alzheimer’s pathology.

Pain Perception

Estrogen modulates central pain processing, which is why many women experience new or worsening musculoskeletal pain and heightened pain sensitivity during perimenopause.

Vascular Tone

Estrogen supports cerebral blood flow and endothelial function in the brain’s vasculature, protecting against small vessel disease and ischemic injury.

When estrogen declines during the menopausal transition, all of these systems are affected simultaneously. The brain fog, the word retrieval failures, the mood instability, the disrupted sleep, the heightened anxiety: these are not separate, unrelated complaints. They are a single coherent neurological picture produced by estrogen withdrawal across multiple brain systems at once.

What the Brain Scans Show

Dr. Lisa Mosconi’s research at Weill Cornell has produced some of the most visually compelling evidence that the menopausal transition is a neurological event, not just a reproductive one. The dip in cerebral glucose metabolism during perimenopause is visible on brain imaging and correlates with the cognitive symptoms women report.

Dr. Lisa Mosconi’s research at Weill Cornell Medicine has done something important: it made the invisible visible. Using PET neuroimaging to measure cerebral glucose metabolism, her team documented what is happening inside the brains of women as they move through the menopausal transition.

The findings are striking. During perimenopause, brain glucose metabolism dips measurably. The brain, deprived of its estrogen signal, becomes less efficient at using its primary fuel. This is not subtle or ambiguous. It shows up on imaging. It correlates with the cognitive symptoms women report. And it is happening in women in their 40s who are years away from any clinical definition of menopause.

The further finding is important for how we think about this: for most women, brain glucose metabolism stabilizes and even partially recovers in the postmenopausal years. The perimenopausal transition is a period of particular neurological vulnerability. It is not necessarily a permanent decline. But for women who are genetically predisposed to Alzheimer’s, or who experience early or surgical menopause, the trajectory may be more consequential.

The Mosconi Research in Context

Mosconi’s neuroimaging work is part of a growing body of evidence establishing menopause as a neurological transition, not merely a reproductive one. The brain changes documented in her cohort were not explained by age alone. They tracked with hormonal status. This has significant implications for when and how we think about brain-protective interventions in women, pointing toward the perimenopausal window as the critical period for intervention.

The APOE4 Factor: Where the Evidence Is Strongest

The signal for MHT and cognitive benefit in APOE4 carriers is one of the more consistent findings in this space, and it contrasts with the absence of a clear protective effect in the general menopausal population.

The APOE4 gene variant is the strongest known genetic risk factor for late-onset Alzheimer’s disease. Approximately 25% of the population carries one copy, and about 2 to 3% carry two copies. Women who carry APOE4 face a disproportionately higher lifetime Alzheimer’s risk compared to men with the same variant, a sex difference that researchers increasingly attribute to the interaction between APOE4 and estrogen signaling.

What the Research Shows

A study using data from the European Prevention of Alzheimer’s Disease (EPAD) cohort, led by Rasha N.M. Saleh and colleagues, found that hormone replacement therapy is associated with improved delayed memory performance and larger entorhinal cortex and amygdala volumes in APOE4 carriers specifically. These are the brain regions most vulnerable to early Alzheimer’s pathology. The effect was not seen in non-carriers. This specificity is important: it suggests that any cognitive benefit of MHT appears concentrated in this high-risk genetic subgroup, not the general menopausal population. Large population-level studies have not demonstrated a protective effect against Alzheimer’s in unselected women. (Saleh et al., 2023, European Prevention of Alzheimer’s Disease cohort)

If you do not know your APOE4 status, it is worth a conversation with your physician. Direct-to-consumer genetic testing also identifies APOE4 status, though interpreting and acting on that information is best done with a clinician. For women who carry the variant, the case for a personalized, informed conversation about MHT timing and dementia risk is particularly strong, and distinct from the guidance that applies to the general population.

“Two thirds of all people living with Alzheimer’s disease are women. We cannot keep treating this as a coincidence.”

What You Can Do Right Now

The evidence-based dementia prevention toolkit maps closely onto the broader menopause health toolkit: the same interventions that protect your heart, bones, and metabolism also protect your brain.

1. Anti-Inflammatory Diet

Neuroinflammation is a core driver of Alzheimer’s pathology. The same Mediterranean-style, whole food, anti-inflammatory eating pattern that protects cardiovascular and metabolic health also protects the brain. Omega-3 fatty acids, particularly DHA, are structural components of neuronal membranes and support brain cell function and anti-inflammatory signaling. Polyphenols from colorful vegetables, berries, and olive oil cross the blood-brain barrier and reduce neuroinflammation directly.

The MIND diet, a hybrid of Mediterranean and DASH eating patterns specifically designed for brain health, has been associated with reduced Alzheimer’s risk in observational studies. Its core components, leafy greens, berries, nuts, beans, whole grains, fish, and olive oil, overlap substantially with the broader anti-inflammatory approach already recommended throughout this series.

2. Regular Exercise

Exercise is the single most evidence-supported modifiable factor for dementia prevention. It increases BDNF (brain-derived neurotrophic factor), the brain’s primary growth factor, which supports neurogenesis, synaptic plasticity, and cognitive reserve. It improves cerebral blood flow, reduces neuroinflammation, and improves insulin sensitivity in the brain, directly countering the glucose metabolism deficits documented in the Mosconi imaging research.

Aerobic exercise, at least 150 minutes per week of moderate intensity, produces the most consistent cognitive benefits. Resistance training adds independent benefit through its effects on insulin sensitivity and inflammatory markers. Combining both is the strongest strategy.

3. Stress Reduction

Chronic psychological stress elevates cortisol, which is directly neurotoxic at sustained levels. Chronically elevated cortisol shrinks the hippocampus, the brain region central to memory formation and one of the first affected by Alzheimer’s pathology. Managing stress is not a soft lifestyle recommendation. It is a neurological one. Deliberate stress reduction practices, whether meditation, breathwork, time in nature, or whatever consistently works for you, are structural requirements for long-term brain health.

4. Menopausal Hormone Therapy: The Timing Hypothesis

The evidence on MHT and Alzheimer’s prevention deserves an honest reading. The short version: large-scale studies in the general menopausal population have not demonstrated a consistent protective effect against dementia from MHT. The Women’s Health Initiative Memory Study (WHIMS), which studied older postmenopausal women using oral conjugated equine estrogen plus progestin, found no cognitive benefit and raised concerns in that specific older population. More recent studies in younger, recently menopausal women are more reassuring and have not shown harm, but they have also not conclusively shown brain protection in unselected women.

Where the signal is stronger and more consistent is in specific high-risk subgroups: women with POI or early menopause, where estrogen is lost decades ahead of schedule, and women who carry the APOE4 variant, where the EPAD cohort data points toward measurable structural and cognitive benefit. For these groups, timely MHT is a reasonable and evidence-informed conversation to have.

For the general menopausal population, MHT used appropriately does not appear to be harmful to cognition, and it may provide indirect brain benefits through its effects on sleep, cardiovascular health, and metabolic function. But the case that it prevents Alzheimer’s across the board is not yet supported by the large-scale evidence. The honest framing is: we do not yet have definitive proof of cognitive protection in average-risk women, but we also have no good reason to avoid MHT on cognitive safety grounds when it is otherwise indicated.

Your Brain Protection Action Plan

• Eat for your brain: Mediterranean or MIND diet pattern, with emphasis on leafy greens, berries, fatty fish, nuts, olive oil, and minimal ultra-processed foods. Omega-3 supplementation at 2 grams per day if dietary fish intake is low.

• Move consistently: 150 minutes of aerobic exercise per week plus resistance training. Exercise is the most evidence-supported dementia prevention strategy available, bar none.

• Know your APOE4 status. Ask your physician or use direct-to-consumer genetic testing. If you carry the variant, the conversation about MHT timing and dementia risk becomes more urgent.

• Discuss MHT in the context of your individual risk profile. If you have POI, early menopause, or carry APOE4, the case for a timely MHT conversation is particularly strong. For average-risk women, MHT does not appear harmful to cognition and carries broad benefits for quality of life and other health outcomes.

• Take stress seriously as a brain health issue. Chronic cortisol elevation is neurotoxic. Build deliberate stress reduction into your daily structure, not as a luxury but as a neurological necessity.

• Protect your sleep. Deep sleep is when the glymphatic system clears amyloid and tau from the brain. Chronically disrupted sleep is associated with accelerated Alzheimer’s pathology accumulation. Sleep is not optional. It is neuroprotective infrastructure.

The Bottom Line

Women develop Alzheimer’s disease at nearly twice the rate of men. The female brain is built in relationship with estrogen. Its loss during the menopausal transition is not a neutral event for the brain. It is a period of genuine neurological vulnerability, visible on imaging, correlating with symptoms women report and are routinely dismissed for, and carrying consequences that may extend across decades.

The brain fog is real. The word retrieval failures are real. And they are telling you something important about what your brain needs right now.

The good news is that the same toolkit that protects your heart, bones, muscles, and metabolism also protects your brain. The interventions that matter, diet, exercise, stress management, sleep, and timely hormonal support, are available to you right now. The window is open. And knowing that the window exists is the first step to using it.

Questions to Ask Your Doctor

1. “Do you know my APOE4 status? If not, should I find out given my family history?”

2. “Do I have any risk factors, such as early menopause, POI, or APOE4 carrier status, that would strengthen the case for MHT from a brain health perspective?”

3. “The brain fog and word retrieval issues I’m experiencing, could these be related to estrogen withdrawal rather than stress or anxiety?”

4. “What cognitive baseline testing would you recommend so we can track any changes over time?”

5. “Are there any inflammatory markers or metabolic factors in my bloodwork that might be contributing to my cognitive symptoms?”

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause and The New Perimenopause | The Pause Life

Post 8 of 10

She was 54, healthy by every standard measure. Normal blood pressure. Normal cholesterol on her annual labs. No family history of early heart disease. She ran three days a week. She did not smoke. Her doctor told her at every visit that her heart was fine.

Four years later she had her first cardiac event.

The problem was not that anything had been missed. Her labs were genuinely normal. Her blood pressure was genuinely controlled. The problem was that none of the standard primary prevention metrics captured what was actually happening inside her arteries during the years when estrogen was withdrawing and atherosclerosis was accelerating. By the time the clinical picture changed, the underlying process had been underway for nearly a decade.

This is the cardiovascular story of menopause: a risk that doubles, a window where accelerated damage occurs, and a prevention framework that was largely built on data from men and does not serve menopausal women as well as it should.

The Risk That Doubles

The doubling of cardiovascular disease risk after menopause is one of the most consistent and consequential findings in women’s health research, and one of the least communicated to women themselves.

Cardiovascular disease risk doubles after menopause. Heart disease is the leading cause of death in women, claiming more lives than all cancers combined.

Heart disease is widely perceived as a man’s disease. It is not. It is the leading cause of death in women in the United States, and it has been for decades. What differs between men and women is not the ultimate outcome, it is the timing and trajectory.

Before menopause, women have substantially lower cardiovascular disease rates than men of the same age. This protection is largely estrogen-mediated. After menopause, that protection is withdrawn. The gap closes rapidly. By her 60s, a woman’s cardiovascular risk profile has converged with a man’s of similar age. By her 70s, it may exceed it.

The years between 45 and 55, precisely the years of perimenopause and early postmenopause, are when the accelerated cardiovascular aging begins. This is the window that matters, and it is the window where current prevention strategies most often fall short.

What Is Happening Inside Your Arteries

Atherosclerosis progression accelerates measurably in women between ages 45 and 55, directly tracking the window of estrogen withdrawal. This is not simply an aging phenomenon. It is a hormonal one.

Atherosclerosis, the buildup of plaque inside arterial walls, is the underlying process that drives most heart attacks and strokes. It develops slowly, silently, over decades. And in women, its rate of progression is not constant. It accelerates during the menopausal transition.

Estrogen is a vascular protector. Its withdrawal removes multiple layers of cardiovascular protection simultaneously.

What Estrogen Does (Protective)

Reduces LDL oxidation and atherogenicity. Reduces LDL binding and accumulation in arterial walls. Reduces cell adhesion molecules and macrophage accumulation. Inhibits smooth muscle cell proliferation. Maintains endothelial function and vasodilation.

What Estrogen Loss Does (Harmful)

Reduces vascular responsiveness. Decreases estrogen receptor expression in vessel walls. Increases ERalpha methylation. Increases matrix metalloproteinase expression, destabilizing existing plaque. Promotes the inflammatory environment that drives lesion progression.

Plaque instability is worth pausing on. The danger of atherosclerosis is not just the presence of plaque. It is the stability of that plaque. Stable plaque can narrow an artery gradually. Unstable plaque, where the fibrous cap is thin and the lipid core is exposed, is the plaque that ruptures and causes sudden heart attacks and strokes. The increase in matrix metalloproteinase expression that follows estrogen withdrawal directly contributes to plaque instability, meaning the cardiovascular risk after menopause is not only about more plaque. It is about more dangerous plaque.

The Vascular Biology in Plain Language

Think of the arterial wall as a carefully maintained barrier. Estrogen helps keep that barrier smooth, flexible, and resistant to the inflammatory cells that want to penetrate it and begin building plaque. When estrogen is withdrawn, the barrier becomes more vulnerable, the inflammatory process accelerates, and the plaque that has been quietly accumulating becomes less stable. The cascade from perimenopause to elevated cardiovascular risk is not mysterious. It is mechanistic. And understanding the mechanism is the first step to interrupting it.

Why the Standard Primary Prevention Framework Falls Short for Women

This finding, from a peer-reviewed source, challenges the routine application of the male-derived primary prevention framework to healthy menopausal women. Lipid-lowering and aspirin therapy have not been conclusively shown to reduce coronary heart disease or overall mortality in women in primary prevention settings.

“Randomized controlled trials have failed to conclusively prove that lipid-lowering and aspirin therapy statistically significantly reduce CHD and overall mortality in women under primary prevention conditions.”

Hodis et al., Climacteric, 2012

This is a statement that stops most people when they first encounter it, because it contradicts one of the most deeply embedded assumptions in cardiovascular medicine: that statins and aspirin are the cornerstones of primary prevention for everyone.

The evidence base for statins in primary prevention, meaning in people who have not yet had a cardiac event, was built overwhelmingly on studies in middle-aged men. When those findings were extended to women, particularly healthy menopausal women without established cardiovascular disease, the benefit has been much harder to demonstrate. This does not mean statins are never appropriate for women. In secondary prevention, after a cardiac event, the evidence for statins is robust across sexes. And for women with familial hypercholesterolemia or very high calculated cardiovascular risk, statins are entirely appropriate.

What it does mean is that reaching for a statin as a reflex response to a rising LDL in a perimenopausal woman, without addressing the hormonal root cause of that LDL change, without accounting for the loss of estrogen’s vascular protection, and without considering whether MHT might address the underlying problem more directly, is not the only or necessarily best approach. The LDL rise in perimenopause is often a hormonal phenomenon. Treating only the downstream marker without addressing the upstream cause is incomplete medicine.

The Timing Hypothesis: Why the Window Matters

The most important concept in menopausal cardiovascular medicine is the timing hypothesis, and it applies here just as it does in the bone and brain discussions.

The Women’s Health Initiative found that combined HRT (conjugated equine estrogen plus medroxyprogesterone acetate) in older postmenopausal women (average age 63, many of whom were more than 10 years past menopause) did not reduce cardiovascular events and, in some analyses, increased risk. This finding, widely misapplied, led to a generation of women being denied hormone therapy based on a study that did not reflect early initiation in recently menopausal women.

The subsequent re-analysis of WHI data by age and time since menopause, combined with observational data and mechanistic research, tells a more nuanced story. Women who begin MHT during perimenopause or within the first few years of menopause, before significant atherosclerotic plaque has accumulated, show cardiovascular benefit. Women who begin MHT a decade or more after menopause, when arterial walls have already undergone structural changes in the absence of estrogen, do not show the same benefit and may face increased risk.

The Timing Hypothesis in Practice

The biological rationale is straightforward. In a healthy artery with minimal plaque burden, estrogen restores the vascular protection it normally provides: endothelial function improves, inflammation decreases, LDL oxidation is reduced. In an artery with established plaque, particularly unstable plaque, the addition of estrogen may trigger inflammatory responses and plaque instability in ways that increase acute event risk. The same hormone. Dramatically different results depending on the state of the vasculature at the time of initiation. This is why timing is not a nuance. It is the central variable.

New Evidence From the WHI: What Age-Stratified Data Actually Shows

A 2025 secondary analysis of the Women’s Health Initiative trials, published in JAMA Internal Medicine (Rossouw et al., 2025), provides the clearest age-stratified cardiovascular data we have to date, and it largely vindicates the timing hypothesis while adding important nuance about older women.

Rossouw et al., JAMA Internal Medicine, November 2025

This secondary analysis of 27,347 postmenopausal women in the WHI trials stratified cardiovascular outcomes by decade of age and vasomotor symptom status. The key findings by age group:

Ages 50 to 59: Both CEE alone and CEE plus MPA reduced vasomotor symptoms without significantly affecting atherosclerotic cardiovascular disease (ASCVD) risk. Absolute risks were low. This age group supports current guideline recommendations for MHT.

Ages 60 to 69: No clear signal of cardiovascular harm from CEE plus MPA. CEE alone showed a trend toward higher ASCVD risk (HR 1.31, confidence intervals crossing 1.0), but the findings were not statistically significant. The authors recommend caution rather than avoidance when initiating MHT in this age group.

Ages 70 and older: Substantially increased ASCVD risk with both CEE alone (HR 1.95, 217 excess events per 10,000 person-years) and CEE plus MPA (HR 3.22, 382 excess events per 10,000 person-years). The evidence clearly argues against initiating MHT in this age group for vasomotor symptom management.

The authors conclude: findings support guideline recommendations for treatment of VMS with HT in women aged 50 to 59 years, caution if initiating HT in women aged 60 to 69 years, and avoidance of HT in women 70 years and older.

What this study does not address is women who began MHT in their 50s and are continuing it into their 60s and 70s, a clinically common scenario. The WHI data reflects initiation at older ages, which is a meaningfully different situation from long-term continuation. That distinction matters and should be part of any individualized shared decision-making conversation with your provider.

The practical takeaway is clear: if you are in your 50s and have symptoms, the evidence supports using MHT. If you are approaching or past 60, the conversation becomes more individualized. And initiating MHT for the first time after 70, without a compelling clinical reason, is not supported by the current evidence.

What You Can Do Right Now

The cardiovascular prevention toolkit for menopausal women differs in important ways from the standard approach. VO2 max is one of the strongest predictors of cardiovascular mortality in women and one of the most underemphasized targets in clinical practice.

1. MHT: Start Early

If you are an appropriate candidate for menopausal hormone therapy and are currently in perimenopause or early postmenopause, the cardiovascular case for timely initiation is strong. Estrogen started during this window, before significant arterial changes have accumulated, directly addresses multiple mechanisms of cardiovascular risk.

This is a shared decision-making conversation with a menopause-informed provider who knows your full clinical picture: your lipid trends, your blood pressure trajectory, your family history, your clotting risk, and your overall cardiovascular risk score. It is not a blanket recommendation for everyone. It is a conversation every perimenopausal woman deserves to have.

2. Aerobic Exercise.

Regular aerobic exercise reduces inflammation, improves insulin sensitivity, lowers blood pressure, and strengthens the heart muscle itself. Consistent aerobic training addresses nearly every upstream driver of cardiovascular disease simultaneously.

The target is 150 minutes per week of moderate intensity cardio. The kind where you are working but can still hold a conversation. Walking, cycling, swimming, dancing. It does not need to be complicated. It needs to be consistent.

Adding one to two sessions per week of higher intensity effort amplifies the benefit significantly, driving adaptations in your heart and blood vessels that moderate exercise alone cannot fully achieve.

Your heart is a muscle. It responds to the demands you place on it. If you are not currently exercising, a 20-minute walk today begins changing your biology immediately. The best time to start was years ago. The second best time is right now.

3. Fiber Above 35 Grams Per Day

Cardiovascular prevention specifically warrants a higher fiber target than the general metabolic recommendation. At this level, soluble fiber directly reduces LDL cholesterol through bile acid binding, reduces systemic inflammation, improves postprandial glucose and insulin responses, and supports the gut microbiome composition associated with cardiovascular protection. Food-first is the goal. Supplementation fills the gap.

4. Added Sugar Below 25 Grams Per Day

Excess dietary sugar drives triglyceride elevation, HDL reduction, hepatic fat accumulation, and systemic inflammation. All of these are independent cardiovascular risk factors, and all of them are worsened by the metabolic shifts of menopause. Reducing added sugar is not just a weight management strategy. It is a cardiovascular one.

5. Know Your Full Cardiovascular Risk Picture

Standard cholesterol panels are a starting point, not an endpoint. For menopausal women, a more complete picture includes LDL particle size and number (small dense LDL is more atherogenic than total LDL), Lp(a), which is a genetically determined cardiovascular risk factor that estrogen normally suppresses and that rises after menopause, high-sensitivity CRP as an inflammatory marker, fasting insulin and HOMA-IR, and in some cases coronary artery calcium (CAC) scoring, which directly measures subclinical atherosclerosis and is a more accurate predictor of cardiovascular events than calculated risk scores alone.

On Lp(a) and MenopauseLipoprotein(a) is a largely genetic cardiovascular risk factor that is not routinely measured but is present in elevated levels in approximately 20% of the population. Estrogen normally suppresses Lp(a) levels. After menopause, Lp(a) rises. For women who carry elevated Lp(a), the post-menopausal period brings a compounded risk that standard lipid panels completely miss. Asking for an Lp(a) measurement once in adulthood is a reasonable cardiovascular screening step for any woman.

Your Cardiovascular Protection Action Plan

• Discuss MHT timing seriously. If you are perimenopausal or recently postmenopausal and appropriate for therapy, the cardiovascular window is open now. It will not be open indefinitely.

• Move consistently and with intention. 150 minutes of moderate intensity cardio per week plus one to two higher intensity sessions. This is the highest-leverage cardiovascular intervention you have direct control over.

• Eat 35+ grams of fiber per day. The cardiovascular target is higher than the general metabolic target. Soluble fiber specifically reduces LDL and inflammatory markers.

• Cut added sugar below 25 grams per day. Triglycerides, HDL, and inflammatory markers all respond directly to dietary sugar reduction.

• Ask for a complete cardiovascular panel, not just standard cholesterol. Request Lp(a) if you have never had it measured. Ask about high-sensitivity CRP. Consider coronary artery calcium scoring if you are in a higher-risk category.

• These are not passive recommendations. They are active decisions that compound over time. Your cardiovascular future is being written right now, by the choices you make today.

The Bottom Line

Heart disease does not announce itself in women the way it does in men. The symptoms present differently. The risk factors accumulate differently. The standard prevention framework was not built for menopausal women. And the window where early intervention makes the most difference, the perimenopausal years, is precisely the window where most women are not having the cardiovascular conversation with their clinicians.

You do not have to wait for a cardiac event to take your cardiovascular health seriously. You do not have to accept that a rising LDL in perimenopause is simply a statin indication. And you do not have to navigate this alone.

The tools exist. The evidence is there. The conversation just needs to happen earlier, more completely, and with the hormonal context that changes everything about how that conversation should go.

Questions to Ask Your Doctor

1. “My lipid profile has changed since perimenopause. Before we discuss statins, can we talk about whether MHT would address the hormonal driver of this?”

2. “Have you measured my Lp(a)? It rises after menopause and standard panels miss it.”

3. “Can we assess my cardiovascular fitness, VO2 max or a functional equivalent, not just my cholesterol?”

4. “Would a coronary artery calcium score be appropriate for me given my menopausal status and risk factors?”

5. “Am I in the window where starting MHT would offer cardiovascular benefit rather than risk?”

Coming in Post 9:

The Menopause Toolkit
Posts 3 through 8 covered the Big Six. Post 9 brings it all together: the complete evidence-based toolkit for navigating menopause with your health intact. Nutrition, movement, sleep, stress, pharmacology, and supplementation, everything in one place, with the why behind each recommendation.

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

I have been waiting to write this post for a long time.

The New Perimenopause is here. And I want to tell you what it is, who it’s for, and why I had to write it even after everything that went into The New Menopause.

Let me start with the dedication. Because everything else flows from it.

For every woman who was told it was all in her head.

For those who were dismissed, misdiagnosed, or handed a vague label and a bottle of antidepressants instead of real answers.

For the clinicians who are listening truly listening and learning alongside their patients, even when the textbooks came up short.

For the researchers who dared to challenge the early conclusions of the Women’s Health Initiative. You faced resistance, skepticism, and institutional inertia, but you pressed on in pursuit of the truth. Because of your courage, an entire generation of women may finally be seen, heard, and cared for with the rigor they deserve.

And for my daughters and yours. May they enter this transition armed with knowledge, supported by science, and empowered by a healthcare system that no longer treats midlife as invisible.

That last line is the one that undoes me every time I read it.

My daughters are in their early to mid twenties. They have no idea what’s coming. And for most of human history, neither did we because no one told us. Not our mothers, not our doctors, not our medical schools. Certainly not the NIH, which dedicates less than one percent of women’s health funding to menopause research. (And that’s one percent of the already-small slice dedicated to women’s health at all.)

The silence was total. And the consequences have been real, measurable, and devastating.

Why this book. Why now. Why perimenopause.

When The New Menopause came out, I was not prepared for what happened next. Women waited in lines to hug me. They pressed notes into my hands. They said: I feel seen. I have the tools now. I finally understand what happened to me.

I was grateful beyond words. And I immediately got back to work.

Because something kept nagging at me. The New Menopause covered perimenopause but perimenopause wasn’t in the spotlight. And it needed to be. Desperately.

Here’s what the data says: until 1977, there were only 35 medical research articles that even mentioned perimenopause. As of today, that number is around 9,000. Compare that to pregnancy: 1.2 million. Menopause: 99,000. Perimenopause is the most underfunded, under-researched, and under-recognized transition in women’s health.

And it starts earlier than almost anyone tells you.

The average age of entering perimenopause is 39 to 48. It can begin in the mid-30s. It can last four years or ten. And it does not announce itself with a skipped period. What we are now understanding is that the brain is often the first organ to register that something is changing, even before the menstrual cycle becomes irregular.

The first symptoms of perimenopause are often neurological: fatigue, brain fog, increased anxiety, the inability to calm down on the inside, crying more, feeling disconnected from yourself. In March 2024, a study published in the journal Menopause named this experience formally: Not Feeling Like Myself. NFLM. The lived patient experience, finally given an academic stamp.

I almost cried when I read it. Because I had spent years watching women walk into my office describing exactly this and for years, I had nothing real to offer them. “It’s just part of being a woman,” I used to say. I am not proud of that. But I tell it because it is true, and because your doctor may be saying it right now, and you deserve to know that it is not the end of the conversation.

It is the beginning of one.

What this book is, and what it is not

The New Menopause was about reclaiming the post-reproductive years: understanding estrogen as a multi-organ hormone, rehabilitating the evidence on hormone therapy, and giving women the tools to push back against decades of fear and silence.

The New Perimenopause is earlier, more urgent, and in some ways more personal.

It is about what is happening to you right now or to the woman in your life who is somewhere between 35 and 50 and cannot figure out why she suddenly feels like a stranger in her own body. It is about the window of vulnerability: the accelerated bone loss, the LDL that spikes 18 percent during the transition, the mental health changes that are biological in origin and only being treated with antidepressants. It is also about the window of opportunity because perimenopause is the moment when the habits you build will determine the trajectory of your health for the next forty years.

This book is structured around both of those truths. Part One places you in the landscape: the Status Quo Woman (a patient story that is, I’m sorry to say, not exceptional), the Zone of Chaos, and the deeply troubling pattern of misdiagnosis and gaslighting. Part Two walks through the organ systems most vulnerable during this transition: brain, mental health, cognition, metabolic health, bone, muscle, sleep. Part Three covers what happens to sex, fertility, and periods. Part Four is where hope lives: hormone therapy, lifestyle foundations, and exactly what to say and test at your next appointment.

The conclusion is called What I Wish I Had Known at 35.

I am 57 years old. I am truly now living my best life. But I missed my window, the years when I could have been building bone and muscle and metabolic resilience, because I was too busy cutting calories and counting points and focusing ONLY on the scale like so many women of my generation. You are not too late. But you also do not have time to wait for medicine to catch up to you.

Who this book is for

It is for the woman who is 38 and has been told her labs are normal and her anxiety is situational.

It is for the woman who is 44 and has been handed an antidepressant when what she needed was a conversation about her hormones.

It is for the woman who is 50 and has spent the last decade being dismissed and is finally, finally, done accepting that.

It is for the clinician who suspects there is more to learn and is ready to learn it.

It is for the daughters mine and yours who deserve to enter this transition with knowledge instead of confusion, with science instead of shame, with a healthcare system that sees them as whole, complex, hormonal human beings rather than a cluster of inexplicable complaints.

It is a love letter to my younger self. It is the guide I did not have. And it is, in every sense of the word, the very best I have to offer.

The New Perimenopause is available now wherever books are sold. If it helps you, tell someone. Give it to a friend. Leave it in your doctor’s waiting room. The movement is built one informed woman at a time.

Knowledge is not fear mongering. Knowledge is freedom.

You are not broken. You are in the Zone of Chaos. And now you have a map.

With so much love,

Mary Claire

She was forty-three when I first saw her. She had been seeing doctors for three years by then. A rotating cast of us. She had been given a sleep aid, an antidepressant, a referral to a gastroenterologist for the bloating, another to a cardiologist for the palpitations. One of her physicians suspected anxiety. One mentioned perimenopause briefly, almost as an aside, before moving on.

I was not that physician.

The first time I saw her, I ran through my usual checklist. I was thorough. I was well-meaning. I was also working within a framework that had never taught me to recognize what was standing right in front of me. She left my office without a diagnosis. She left without the word that might have changed the next three years of her life.

She was in perimenopause. I just did not know enough to say so.

That is the confession I want to open with. Not as a book announcement, but as a clinical reckoning. Because The New Perimenopause was written from inside that failure. It was written because I was part of the problem before I understood what the problem was.

What Is Perimenopause, and When Does It Start?

Perimenopause is not a moment. It is not the year before your last period. It is not something that begins when your cycle becomes irregular.

Perimenopause is a hormonal transition that can begin in the mid-to-late thirties and last up to a decade. During this time, estrogen does not decline in a neat, predictable slope. It swings. It surges. It crashes. And in the middle of that chaos, the brain, the cardiovascular system, the bones, the metabolic system, and the sleep architecture are all responding in real time.

Irregular periods are often the last symptom to arrive, not the first. But most clinical guidance still anchors the diagnosis of perimenopause to cycle changes. Which means that the majority of symptomatic women, the ones presenting with anxiety, brain fog, insomnia, joint pain, weight redistribution, heart palpitations, and mood instability, are being missed entirely.

What Are the First Signs of Perimenopause?

In a community survey I conducted in 2024 with more than eight hundred perimenopausal women, the most commonly reported symptoms were:

• Hot flashes and night sweats: 85.9%

• Weight gain and redistribution: 82.4%

• Anxiety, depression, or panic attacks: 82.3%

• Sleep disturbances: 81.7%

These are not edge-case symptoms. They are the defining experience of a decade-long hormonal transition that medicine has systematically failed to name.

The brain is frequently the first organ to respond. Emotional symptoms, including the feeling of not being able to calm down on the inside, increased crying, difficulty with concentration and decisions, and a pervasive sense of “not feeling like myself,” may be among the earliest indicators that hormones are shifting into perimenopause. This was confirmed in research published in the journal Menopause in 2024. The title alone stopped me: “Not Feeling Like Myself” in Perimenopause. The lived patient experience, finally given an academic stamp. A biological reality that medicine had been filing under stress, or age, or anxiety disorder, or just the ordinary burden of being a woman in midlife.

What Happens When Perimenopause Goes Undiagnosed?

The diagnostic gap is not a neutral space. It has a clinical cost, and women pay it entirely.

While perimenopause goes unnamed, the downstream consequences are accumulating:

Bone density loss begins in earnest during the perimenopausal window, years before most women receive a first DEXA scan.

Cardiovascular risk rises as estrogen fluctuates. The heart and blood vessels are estrogen-sensitive tissues, and the instability of perimenopause matters for long-term cardiac health.

Sarcopenia (age-related muscle loss) accelerates when the hormonal scaffolding that supports muscle tissue destabilizes.

Metabolic changes create new insulin resistance and weight redistribution that no amount of calorie restriction will reverse. The problem is not calories. The problem is estrogen.

Why Are So Many Women Misdiagnosed During Perimenopause?

Instead of receiving a perimenopause diagnosis, many women are sent on a diagnostic detour. They are diagnosed with fibromyalgia, adrenal fatigue, long COVID, depression, or anxiety. Not because those diagnoses are always wrong, but because the physician never asked whether hormones were driving the symptoms. They are prescribed SSRIs, sleep aids, benzodiazepines, and statins. They are told to eat less, exercise more, relax, and come back in a year.

Polypharmacy becomes the shape of their healthcare. Multiple medications treating individual symptoms while the root hormonal disruption continues unchecked.

The misdiagnosis patterns I see repeatedly in clinical practice are not flukes. They are the structural consequence of a medical system that was not taught to look for perimenopause in a woman who still has her period. A system not taught to consider estrogen when a forty-year-old presents with joint pain, brain fog, or a sudden inability to handle stress she managed easily for twenty years.

I was not taught this either. That is the part I have had to sit with.

The early perimenopausal years are precisely when lifestyle interventions, and in appropriate candidates, hormone therapy, can have the most meaningful impact on long-term cardiovascular, cognitive, and skeletal health. The window is not infinite. Inaction is not waiting. Inaction is a clinical decision with consequences that compound over years.

What Does The New Perimenopause Provide That Other Books Do Not?

The New Perimenopause is not a wellness guide. It is not a collection of lifestyle tips dressed up in scientific language.

It is a clinical reference written for women, with the evidence, the language, the diagnostic framework, and the specific questions a woman needs to walk into an appointment and refuse to leave without answers. It covers what perimenopause does to the brain, to the cardiovascular system, to bone density and muscle mass and sleep architecture. It covers the symptom clusters most likely to be misdiagnosed, and what to say to a physician who has not been trained to recognize them. It includes the talking points and lab tests you need for your next appointment, because you should not have to show up uninformed and hope for the best.

Chapter 3 is called “The Troubling Pattern of Misdiagnosis (and Gaslighting).” I did not give it that title lightly. What I have seen, and what I have participated in, is not a series of isolated clinical oversights. It is a pattern. And patterns require a structural response.

The conclusion is titled “What I Wish I’d Known at Thirty-Five.” I was fifty-seven when I finished writing it. The distance between those two numbers is the cost of the silence.

This book is the appointment that woman in my office should have had years earlier. It is the appointment a lot of you should have had years earlier.

You are not anxious. You are not burned out. You are not aging badly. You may be in perimenopause. And there is much that can be done about it, if someone finally tells you that is where you are.

The New Perimenopause is available for preorder now.

What You Really Need to Know About Menopause

Post 5 of 10

She was doing everything right. Eating carefully. Exercising consistently. The habits that had kept her weight stable for twenty years were suddenly not working. The scale crept up. Her waist expanded. Her energy crashed after meals in a way it never had before. Her doctor ran bloodwork, told her everything was normal, and suggested she try eating less.

She was not eating too much. She was not exercising too little. She was experiencing insulin resistance, driven in large part by estrogen withdrawal, and nobody had connected those dots for her.

This is one of the most common and most mismanaged metabolic shifts in women’s health. It is not a character flaw. It is not laziness. It is a predictable biological consequence of the hormonal transition that every woman who lives long enough will go through, and it deserves a real explanation.

The Statistic That Reframes the Conversation

This is not a subtle difference. A two to three times higher rate of metabolic syndrome in postmenopausal women compared to premenopausal women of the same age points directly to estrogen withdrawal as a primary driver.

2–3×Postmenopausal women have two to three times the prevalence of metabolic syndrome compared to premenopausal women of the same age.

Same age. Same generation. Same general life context. The primary variable is hormonal status. That is not a coincidence. That is a mechanism.

Metabolic syndrome is not a single disease. It is a cluster of conditions that appear together and dramatically raise the risk of type 2 diabetes, cardiovascular disease, stroke, and fatty liver disease. The cluster includes elevated fasting blood glucose, high triglycerides, low HDL cholesterol, high blood pressure, and excess abdominal fat. When you see all five showing up in a woman in her 50s who had none of them in her 40s, estrogen withdrawal is a likely driver of the shift.

How Estrogen Loss Disrupts Insulin Signaling

Estrogen deficiency disrupts insulin signaling simultaneously across four major tissue types. The result is a system-wide shift toward insulin resistance, elevated blood glucose, and fat redistribution.

The diagram above shows exactly why insulin resistance is a direct and predictable consequence of estrogen loss. Estrogen does not just regulate reproduction. It is deeply embedded in metabolic function, and its withdrawal triggers a cascade across four distinct tissue types.

Pancreatic Beta Cells: Estrogen supports beta cell survival and insulin secretion. Without it, insulin output becomes impaired, meaning the pancreas cannot keep up with rising glucose levels.

Skeletal Muscle: Muscle is the primary site of glucose disposal in the body. Estrogen supports glucose uptake in muscle tissue. When it falls, glucose stays in the bloodstream longer after meals.

Liver: Estrogen suppresses hepatic gluconeogenesis (glucose production by the liver). Without this brake, the liver produces more glucose even when blood levels are already elevated. It also increases lipogenesis and VLDL production, contributing to elevated triglycerides.

Adipose Tissue: Estrogen regulates fat storage and adipocyte size. Without it, lipolysis increases, adipocytes enlarge, and visceral fat accumulates, all of which drive systemic inflammation and further worsen insulin resistance.

These four pathways operate simultaneously. Insulin resistance in menopause is not a single-point failure. It is a system-wide metabolic shift, happening in parallel across the tissues that together regulate blood glucose. That is why it feels so dramatic and so sudden. It is.

Why This Is Not Just About Diabetes: Insulin resistance is not only a precursor to type 2 diabetes. Chronically elevated insulin drives fat storage, particularly visceral fat accumulation, which is itself a pro-inflammatory organ. Elevated insulin also promotes cell proliferation, contributes to cardiovascular risk, and is associated with increased risk of certain cancers. Addressing insulin resistance in menopause is not just about blood sugar. It is about the entire downstream cascade that chronic metabolic dysfunction produces.

Know Your Numbers: The HOMA-IR Score

One of the most useful tools you have probably never been offered is the HOMA-IR calculation. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) uses a simple formula combining your fasting insulin and fasting glucose to estimate how insulin resistant you are right now, before you develop prediabetes or diabetes.

The formula: (fasting insulin in mIU/L x fasting glucose in mmol/L) divided by 22.5. A score below 1.0 is optimal. Above 1.9 suggests early insulin resistance. Above 2.9 is significant insulin resistance.

Most standard metabolic panels do not include fasting insulin. You have to ask for it specifically. But the number is enormously useful because it gives you early warning, during the window where lifestyle interventions are most effective, before a diagnosis of prediabetes or diabetes forces the conversation.

Ask your doctor for a fasting insulin level at your next visit. Calculate your HOMA-IR score. Know where you stand.

What You Can Do Right Now

The tools for preventing and addressing insulin resistance in menopause are well-supported by evidence and available right now. The earlier you start, the more you preserve.

1. Fiber: More Than You Think You Need

Dietary fiber slows glucose absorption, feeds the gut microbiome, reduces postprandial insulin spikes, and directly improves insulin sensitivity over time. The target for women is greater than 25 grams per day. Most women are getting 12 to 15 grams. The gap is significant.

Food sources first: legumes, vegetables, whole grains, berries, nuts, seeds. Fiber supplements can fill the gap when dietary sources fall short. This is a daily, consistent practice, not an occasional intervention.

2. Cut Added Sugar Below 25 Grams Per Day

Every gram of added sugar is a glucose and insulin spike your increasingly resistant cells have to manage. The American Heart Association recommends less than 25 grams of added sugar per day for women. Most women consuming a standard diet are at two to three times that level without realizing it.

This is distinct from the natural sugars found in whole fruit, which arrive with fiber that blunts the glucose response. Added sugars in processed foods, beverages, condiments, and sweetened dairy products are the primary culprits. Read labels. Track for a week. The number will surprise you.

3. Exercise, Specifically Resistance Training

Skeletal muscle is the body’s primary site of glucose disposal. The more muscle you have, and the more metabolically active it is, the more glucose your body can clear after meals without requiring excessive insulin. Resistance training builds and maintains this metabolic buffer. Cardiovascular exercise, particularly zone 2 cardio, improves mitochondrial efficiency and insulin sensitivity in muscle tissue.

Exercise after meals is particularly effective at blunting postprandial glucose spikes. Even a 10 to 15 minute walk after eating meaningfully reduces the glucose and insulin response.

4. Menopausal Hormone Therapy

MHT addresses insulin resistance at its hormonal root. By restoring estrogen signaling, it directly supports pancreatic beta cell function, muscle glucose uptake, and hepatic glucose regulation. The evidence that MHT reduces the risk of type 2 diabetes in perimenopausal and early postmenopausal women is compelling and clinically underutilized.

This study followed perimenopausal individuals with prediabetes for 20 years and found a sustained reduction in diabetes risk among those who used menopausal hormone therapy. This is not a short-term effect.

What the Research Shows: A study by Shih et al. demonstrated a sustained 20-year decrease in the risk of diabetes among perimenopausal individuals with pre-diabetes who underwent menopausal hormone therapy. This is a remarkable finding. The benefit was not temporary and did not disappear when therapy was discontinued. It reflects the importance of the perimenopausal window: intervening during the transition, before insulin resistance becomes entrenched, produces lasting metabolic protection. (Shih, Yang, Wang, Lung, 2023)

5. Targeted Supplementation

Berberine is a plant-derived compound with well-documented effects on insulin sensitivity. It activates AMPK (the same pathway targeted by metformin), improves glucose uptake in muscle, and reduces hepatic glucose production. Multiple studies support its use for improving insulin resistance and lowering fasting glucose. 500 mg two to three times per day with meals is the typical protocol.

Magnesium is a cofactor in more than 300 enzymatic reactions, including glucose metabolism and insulin signaling. Magnesium deficiency is common in women with insulin resistance and worsens the condition. Magnesium glycinate or magnesium citrate at 200 to 400 mg daily is a reasonable supplementation strategy.

Zinc plays a direct role in insulin synthesis and secretion within pancreatic beta cells. Low zinc is associated with impaired insulin function. Dietary sources include meat, shellfish, legumes, and seeds. Supplementation at 8 to 11 mg per day is appropriate when dietary intake is insufficient.

Probiotics influence insulin sensitivity through the gut-metabolic axis. Specific strains, particularly Lactobacillus and Bifidobacterium species, have been shown to improve glycemic control and reduce inflammatory markers associated with insulin resistance. A high-quality multi-species probiotic is a reasonable addition to a metabolic health strategy.

6. Anti-Inflammatory, Low Glycemic Index Eating

The overall quality and composition of your diet matters beyond individual nutrients. A Mediterranean-style, anti-inflammatory eating pattern, characterized by abundant vegetables, legumes, whole grains, healthy fats, lean protein, and minimal ultra-processed foods, consistently improves insulin sensitivity across study populations. Low glycemic index foods blunt postprandial glucose spikes, reducing the insulin burden on already-stressed beta cells.

Your Metabolic Health Action Plan

• Ask for a fasting insulin level at your next appointment. Calculate your HOMA-IR score. Know your baseline before symptoms tell you something is wrong.

• Hit 25+ grams of fiber per day, from food first, supplementation as needed. Track it for a week to know your actual intake.

• Cut added sugars below 25 grams per day. Read labels. The sources will surprise you.

• Walk after meals. Even 10 to 15 minutes meaningfully reduces postprandial glucose. This is one of the most accessible and effective metabolic interventions available.

• Resistance train consistently. Muscle mass is your metabolic reserve. Building and maintaining it is the single most powerful long-term strategy for insulin sensitivity.

• Consider berberine, magnesium, and zinc if dietary sources are insufficient. Discuss with your provider in the context of your current medications and labs.

• Discuss MHT with a menopause-informed provider. If you are perimenopausal with early signs of insulin resistance, the window for hormonal intervention is open right now.

The Bottom Line

Your metabolism did not betray you. It responded exactly as expected to the withdrawal of a hormone that was supporting its function for decades. The shift in insulin sensitivity, the changes in blood glucose, the weight that moves differently now and settles in different places, these are not personal failures. They are physiological consequences of a transition that medicine has been slow to take seriously.

The good news is that insulin resistance at this stage is responsive to intervention. The tools work. The window is open. And unlike so many things in medicine, the most powerful interventions are things you can start today, without a prescription.

Know your numbers. Eat for your metabolism. Build your muscle. And have the conversation your doctor may not have started yet.

Questions to Ask Your Doctor

1. “Can you add a fasting insulin level to my next bloodwork so we can calculate my HOMA-IR score?”

2. “My metabolic markers have shifted since perimenopause. Could estrogen withdrawal be a driver of this?”

3. “Would MHT be appropriate for me given my metabolic risk profile?”

4. “Is berberine something I can safely add given my current medications and bloodwork?”

5. “Can we track my metabolic markers over time so we catch any deterioration before it becomes a diagnosis?”

Coming in Post 6:

The Belly Fat Is Not Your Fault
Before menopause, the average woman carries about 8% of her total body fat as visceral fat. After menopause, that number rises to 23%. Visceral fat is not just cosmetic. It is a pro-inflammatory organ that drives cardiovascular disease, insulin resistance, and metabolic dysfunction. Post 6 covers what visceral fat actually is, why it accumulates during menopause, and the most evidence-supported strategies for addressing it.

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

What Every Woman Needs to Know About Menopause and Muscle Loss

Post 4 of 10

She was 52, fit by any reasonable definition. She exercised. She watched what she ate. She was not overweight. But something had shifted in the last few years that she could not quite name. Her clothes fit differently, even at the same weight. She tired more easily. The workouts that used to feel strong felt harder than they should.

She was not imagining it. And it was not just aging.

What she was experiencing had a name: sarcopenia. The progressive loss of skeletal muscle mass and strength that begins in a woman’s 40s, accelerates sharply with the hormonal changes of perimenopause, and quietly drives some of the most serious health consequences women face in the second half of their lives.

We talk about bone. We talk about hot flashes. We almost never talk about muscle. That is a mistake, because muscle may be the single most geroprotective tissue in the female body. And right now, in the perimenopausal and early postmenopausal years, is the moment that matters most for protecting it.

The Statistic That Changes How You Understand Muscle Loss in Menopause

Premature ovarian insufficiency (POI) dramatically illustrates how central estrogen is to muscle mass maintenance in women.

Premature ovarian insufficiency (POI) increases the risk of low muscle mass by a factor of four. When estrogen is withdrawn early, muscle loss follows. This is not a coincidence. It is cause and effect.

This statistic does something important. It removes the ambiguity. We often talk about muscle loss in midlife as if it is an inevitable consequence of getting older, the product of too many years and too little activity. But women with POI are often in their 20s and 30s. They are not sedentary. They are not elderly. They are simply estrogen-deficient.

The message is direct: estrogen is not just a reproductive hormone. It is a muscle-maintaining hormone. And when it leaves, muscle follows, regardless of age.

What Happens to Your Muscle Mass During Perimenopause and Aging

The rate of muscle loss is not constant. It accelerates with age, and with estrogen withdrawal, creating a compounding problem that is far easier to prevent than reverse.

7–8% muscle mass lost per decade starting in your 40s

15% rate of loss per decade after age 70

25% total muscle mass lost by the time a woman reaches 70

A quarter of your muscle mass. Gone by 70. And that trajectory accelerates at exactly the moment when estrogen is declining most rapidly.

The conventional framing of sarcopenia is that it is an aging problem. The more precise framing is that it is a hormonal problem that aging compounds. The two processes overlap in midlife, and the combination creates a window of vulnerability that most women do not know they are in until the consequences are already underway.

How Estrogen Loss Drives Muscle Loss in Midlife Women

Left: estrogen acts on skeletal muscle and mitochondria through estrogen receptors, regulating everything from satellite cell activity to mitochondrial efficiency. Right: a CT cross-section of the thigh shows the dramatic difference between healthy and sarcopenic muscle tissue.

The CT images on the right of that slide are worth pausing on. The left thigh shows dense, healthy muscle tissue with minimal fat infiltration. The right thigh, from a sarcopenic individual, shows a dramatically reduced muscle cross-section surrounded by fat. This is what we are trying to prevent. And this is what happens, progressively and silently, when the hormonal support for muscle maintenance is removed.

Estrogen acts on skeletal muscle through estrogen receptors (ER) embedded in muscle cells themselves. The effects are substantial:

Muscle mass regulation and regeneration. Estrogen supports satellite cells, the stem cells of muscle tissue that are responsible for repair and growth after exercise. Without estrogen, satellite cell activity declines, and the muscle’s ability to rebuild from training is impaired.

Mitochondrial function. Estrogen supports the mitochondria within muscle cells, enhancing ATP production, beta-oxidation of fats, and the overall energy efficiency of muscle tissue. When estrogen falls, mitochondrial function degrades, contributing to the fatigue and reduced exercise capacity that many perimenopausal women notice and attribute to stress or poor sleep.

Lipid metabolism. Estrogen helps regulate how fat is stored in and around muscle tissue. With estrogen withdrawal, intramuscular fat infiltration increases, which is visible in the CT comparison and contributes to the reduction in muscle quality even when muscle quantity appears preserved on the scale.

The Science Behind Estrogen and Muscle Loss Explained

The estrogen-muscle connection is mediated through both classical nuclear estrogen receptors (ER-alpha and ER-beta) and membrane-bound receptors that regulate rapid cellular signaling. Estrogen’s role in supporting satellite cell activity is particularly significant because satellite cells are what allow muscle to adapt and grow in response to resistance training. A decline in their activity helps explain why women in perimenopause often find that training produces fewer results than it used to, even at the same effort level.

The Muscle Loss Curve That Predicts Strength, Frailty, and Independence

Two women, different trajectories. The healthy lifestyle curve stays above the disability threshold throughout life. The unhealthy lifestyle curve crosses it in midlife. The decisions made in your 40s and 50s determine which curve you are on.

This graphic is one of the most important images in the presentation, and I want to make sure it lands.

The horizontal dashed line is the theoretical disability threshold, the point below which muscle mass becomes insufficient to support independent daily function. Both curves start in the same place and peak in early adulthood. But they diverge sharply in midlife.

The woman on the healthy lifestyle trajectory maintains enough muscle mass to stay well above the disability threshold into her 80s and beyond. The woman on the unhealthy lifestyle trajectory crosses the threshold in her 60s or earlier, entering a zone where routine physical tasks become effortful, falls become likely, and independence becomes fragile.

What determines which curve you are on? Genetic and environmental factors play a role. But so do the choices made during the years when muscle loss is accelerating: whether you are resistance training, whether you are eating enough protein, whether you are sleeping and managing stress, and whether the hormonal changes of menopause are being addressed rather than ignored.

The perimenopause and early postmenopause years are the inflection point on this curve. This is when the trajectories diverge. This is the window.

How to Prevent Muscle Loss in Perimenopause Starting Now

The prevention toolkit for sarcopenia is well-supported by evidence and available to every woman right now. The key is starting before the loss becomes clinically significant.

1. Why Resistance Training Is Essential to Prevent Muscle Loss After 40

This is not optional. It is the most powerful intervention available for preserving and building muscle mass at any age, and it becomes more critical with every passing year after 40.

Progressive resistance training means consistently challenging your muscles with loads that increase over time. Three days per week, structured around a push-pull-legs framework or equivalent, is the minimum effective dose. The goal is not to look a certain way. The goal is to maintain the muscle mass that keeps you functional, metabolically healthy, and above the disability threshold for the rest of your life.

The evidence is unambiguous. Resistance training stimulates satellite cell activity, preserves muscle fiber cross-sectional area, improves mitochondrial function, and directly counteracts many of the mechanisms through which estrogen withdrawal accelerates muscle loss.

2. How Much Protein Women Need to Maintain Muscle in Midlife

Data from the Women’s Health Initiative found that women with protein intake of 1.6 grams per kilogram had the lowest risk of frailty. Protein intake alone is not enough, but it is essential. The combination of protein and resistance training is where the real benefit lives.

Muscle protein synthesis requires amino acids. Without adequate dietary protein, resistance training cannot produce its full benefit, and the body will catabolize muscle tissue to meet its protein needs during periods of low intake.

The target is 1.3 to 1.6 grams of protein per kilogram of ideal body weight per day. For most women, this is significantly more than they are currently eating. Track your intake for one week. The number is almost always a surprise.

Distribution matters too. Spreading protein intake across meals, aiming for at least 30 to 40 grams per meal, maximizes muscle protein synthesis more effectively than front-loading or back-loading intake.

What the Women’s Health Initiative Shows About Protein and Frailty Risk

Data from the Women’s Health Initiative found that women consuming protein at approximately 1.6 grams per kilogram had the lowest risk of frailty, one of the most serious downstream consequences of sarcopenia. Critically, the benefit required both protein intake and resistance training. Eating protein without training does not fully preserve muscle. Training without adequate protein does not either. Both are required.

3. How Creatine Supports Muscle Strength and Performance in Women

Creatine is one of the most studied and most underutilized supplements in women’s health. It supports the phosphocreatine energy system in muscle tissue, enhancing the capacity for high-intensity effort, improving training performance, and directly supporting muscle protein synthesis.

The evidence for creatine in postmenopausal women specifically is growing. Studies show improvements in muscle strength, lean mass, and functional performance when creatine is combined with resistance training. Five grams per day is the standard supplementation dose, and it is safe for long-term use.

Many women are hesitant about creatine because of outdated associations with bodybuilding culture. That hesitation is worth setting aside. Creatine at five grams per day is not about bulk. It is about maintaining the muscle tissue that determines your independence, metabolic health, and resilience as you age.

4. Can Hormone Therapy Help Prevent Muscle Loss in Menopause

The question mark next to MHT on the sarcopenia prevention slide reflects the current state of the evidence: the data is promising but not yet definitive for muscle mass specifically. What we know is that estrogen supports the cellular machinery of muscle maintenance, that women who use MHT report less perceived muscle loss and fatigue, and that the broader metabolic benefits of MHT (reduced visceral fat, improved insulin sensitivity, better sleep) all support the muscle-preserving lifestyle choices that matter most.

For women who are appropriate candidates, MHT during the perimenopausal window is a reasonable component of a comprehensive muscle preservation strategy, not a replacement for training and nutrition, but a supportive foundation.

5. How Sleep and Stress Directly Impact Muscle Loss in Midlife

Muscle is built during recovery, not during training. Poor sleep and chronic elevated cortisol are both directly catabolic to muscle tissue. Cortisol promotes muscle protein breakdown. Sleep deprivation impairs growth hormone secretion, which is a key driver of overnight muscle repair.

This is not a soft recommendation. Inadequate sleep and unmanaged chronic stress can meaningfully undermine even excellent training and nutrition habits. Prioritizing 7 to 9 hours of sleep and building deliberate stress reduction practices into daily life are structural requirements for muscle preservation, not optional additions.

Your Step by Step Plan to Build and Preserve Muscle After 40

• Lift weights three days per week, minimum, with progressive load. Push day, pull day, leg day. Increase the load over time. This is the non-negotiable foundation.

• Hit your protein target daily: 1.3 to 1.6 grams per kilogram of ideal body weight. Track it for at least one week to know your actual baseline.

• Take creatine: 5 grams per day, consistently. Safe, inexpensive, and one of the most evidence-supported supplements available for muscle preservation in midlife women.

• Protect your sleep. Aim for 7 to 9 hours. Poor sleep is directly catabolic. It undermines everything else on this list.

• Manage chronic stress actively. Elevated cortisol breaks down muscle. Stress reduction is not a luxury. It is a physiological requirement for muscle health.

• Discuss MHT with a menopause-informed provider. If you are in the perimenopausal window, the hormonal foundation matters for your muscle-building efforts.

The Bottom Line

The muscle you build and maintain in your 40s and 50s is the muscle that will determine your quality of life in your 60s, 70s, and beyond. It is not vanity. It is not athleticism. It is the biological infrastructure of independence.

Sarcopenia is not inevitable. It is the predictable outcome of unaddressed estrogen loss compounded by inadequate protein, insufficient resistance training, poor sleep, and chronic stress. Every one of those drivers is modifiable. Every one of them is within your control.

You are not getting weaker because you are getting older. You are getting weaker because the hormonal and nutritional support your muscles need has been quietly withdrawn, and no one told you that you needed to fight back.

Now you know. Start fighting back.

Want to dive deeper into what’s happening to your body and exactly what you can do about it? The New Perimenopause is the evidence-based treatment guide you’ve been looking for. It releases April 7th and is available for preorder now.

Questions to Ask Your Doctor

1. “Can we assess my muscle mass, not just my weight? An InBody scan or DEXA with body composition data would help me understand where I stand.”

2. “What protein intake would you recommend for someone at my stage of menopause and activity level?”

3. “Is creatine supplementation appropriate for me given my overall health?”

4. “Are my sleep quality or cortisol levels worth evaluating in the context of my fatigue and body composition changes?”

Coming in Post 5:

Your Metabolism Didn’t Betray You
Postmenopausal women have two to three times the prevalence of metabolic syndrome compared to premenopausal women the same age. This is not a willpower problem. It is an estrogen problem. Post 5 covers the estrogen-insulin connection, why your metabolism shifted during perimenopause, and exactly what you can do to address it at the root.

This spring I’m hitting the road, and I want you there.

On April 7, The New Perimenopause officially releases. This is the book I wish I could have handed every patient who sat across from me confused, dismissed, and convinced something was deeply wrong with her. Because something was happening to her. She just deserved someone to explain it.

Perimenopause can start in your mid-thirties. It can last a decade. It is the phase of life when your brain, your heart, your bones, your mood, your sleep, and your sense of self are all quietly shifting, and almost nobody is talking about it with any honesty or precision. This book does.

Inside you will find the science of what is actually happening in your body during the years before your final period, why your symptoms are biological and not psychological, what the research says about hormones, nutrition, sleep, muscle, and brain health, and exactly what questions to bring to your doctor. In plain terms, no hedging, no permission-seeking.

To celebrate the release I am bringing this conversation to seven cities this spring:

Washington, DC — April 9 | Sixth & I with Norah O’Donnell

Boston, MA — April 10 | Harvard Book Store

Los Angeles, CA — April 18 | The Wiltern with Molly Sims

Kansas City, MO — April 28 | Rainy Day Books

Chicago, IL — April 29 | The Book Stall

Charleston, SC — April 30 | Buxton Books with Dr. Kate White

Salem, NC — May 1 | Bookmarks

If you are anywhere near these cities I would love to meet you. Bring your questions, bring a friend, bring your sister, bring your mother. These events are for every woman who has ever been told her symptoms were just stress.

The New Perimenopause is available for preorder right now at thepauselife.com/pages/the-new-perimenopause-book. Preorders matter enormously for a book’s reach, and every one helps get this information to more women who need it.

Tickets and full event details are at thepauselife.com/pages/events.

Menopause is inevitable. Suffering is not. Let’s keep going, together.

Menopause Explained: Evidence-Based Health Guides for Midlife Women

Menopause Health Series | Post 3 of 10

Topic: Osteoporosis, Bone Loss, and Fracture Prevention in Midlife Women

She did not know anything was wrong. No pain. No warning. She bent over to pick up a bag of groceries, felt a pop in her back, and spent the next six weeks unable to get off the couch. When the imaging came back, her spine showed three compression fractures. She was 59 years old. She had no idea her bones had been quietly eroding for more than a decade.

This is not a rare story. This is the most common story. And it is happening because the conversation about menopause and bone health is starting too late, or not happening at all.

Osteoporosis is the silent disease of menopause. It does not announce itself. It does not cause pain until after the damage is done. And in a medical system that still treats menopause primarily as a hot flash problem, the bone story gets almost no airtime until a woman is sitting in an emergency room with a fractured hip.

That has to change. And it can, because the tools to prevent this exist right now.

The Hip Fracture Statistic Every Woman Should Know

The mortality data on hip fractures after 65 is one of the most sobering statistics in all of women’s health, and one of the least discussed.

If a woman falls and breaks her hip after the age of 65, the risk of death within one year is 79% if the fracture is not surgically repaired. Even with surgical repair, that number drops to only 29%. Nearly one in three women who fracture a hip will not be alive twelve months later.

Read that again. Not just hospitalized. Not just immobilized. Dead.

And yet, for most women, osteoporosis screening is not recommended until age 65. The first bone density test happens after the first fracture. We are diagnosing this disease in the wreckage it leaves behind, instead of identifying it twenty years earlier when we could actually stop it.

Hip fractures initiate a cascade that is hard to survive. Immobility leads to blood clots, pneumonia, rapid muscle loss, and metabolic decline. The independence a woman has spent decades building can vanish in a single fall down a single set of stairs.

This is what bone loss looks like at its end stage. The question is: what does it look like at the beginning? And when does it start?

Osteoporosis in Women: What the Research Actually Shows

The scale of osteoporosis in women remains widely underappreciated, even among clinicians who see these patients every day.

Twice as many women as men have osteoporosis. This is not a small difference. It reflects a fundamental biological reality: estrogen is the primary regulator of bone density in women, and when estrogen falls, bone follows.

50% of women will have an osteoporotic fracture in their lifetime. One in two. That is not a rare complication. That is a near-majority outcome. Spine fractures, wrist fractures, hip fractures. Many of them silent. Many of them preventable.

The fastest bone loss of a woman’s life happens during perimenopause, not in her 70s. This is the piece that most people miss. We think of osteoporosis as an old woman’s disease. But the critical window of accelerated bone loss is the 7 to 10 years surrounding the menopausal transition, often beginning in a woman’s mid-40s. By the time she qualifies for her first DEXA scan at 65, that bone has been gone for twenty years.

Most women are diagnosed after a fracture. Not before. Not with a screening test that could have prompted earlier intervention. After. This is the medical equivalent of diagnosing a heart attack at autopsy.

50% of women will experience an osteoporotic fracture in their lifetime.
Most will not know they have osteoporosis until it happens.

Why Estrogen Protects Bone Density During Menopause

Estrogen protects bone through multiple simultaneous mechanisms. When estrogen is removed, the balance tips sharply toward bone breakdown.

Bone is not static. It is living tissue that is constantly being broken down and rebuilt through a process called remodeling, managed by three types of cells working in careful balance.

Osteoclasts break down old bone. Osteoblasts build new bone. Osteocytes are the sensor network embedded within bone tissue, coordinating the whole process.

Estrogen acts on all three. It promotes osteoblast survival and function, keeping the bone-building side of the equation robust. It promotes osteoclast apoptosis, keeping bone breakdown in check. It reduces NF-kB activity and oxidative stress, protecting the cellular machinery of bone formation. It regulates T-cell activity, which plays a role in inflammatory bone resorption.

When estrogen drops, this entire system goes out of balance. Osteoclast activity surges. Osteoblast activity falls. The result is net bone loss, happening rapidly during the menopausal transition and continuing at a slower pace into postmenopause.

The Science Behind Estrogen and Bone Loss

This mechanism is well-established in the literature. Estrogen’s protective effects on bone operate through genomic and non-genomic pathways, including direct receptor binding in osteoblasts and osteocytes, as well as indirect effects through immune cell regulation. The perimenopausal acceleration of bone loss, now documented across multiple longitudinal studies, is a direct consequence of this withdrawal.

How to Prevent Osteoporosis During Perimenopause and Menopause

Prevention is not complicated, but it requires starting earlier than most women are told. The window to make a difference is open right now.

Here is where the story stops being frightening and starts being actionable. The research base on osteoporosis prevention is actually quite strong. We know what works. The problem is not lack of evidence. It is lack of urgency in applying it early enough.

1. Menopausal Hormone Therapy (MHT) and Bone Protection

Estrogen is a first-line strategy for bone protection in the menopausal transition, and for good reason. The mechanism is direct: replacing estrogen restores the bone-remodeling balance that estrogen withdrawal disrupts. Multiple studies confirm that MHT reduces bone loss and fracture risk, particularly when started during perimenopause or early postmenopause.

What the Research Shows

Managing estrogen loss at menopause is recognized as an important bone-protective strategy in selected patients. In guidelines and systematic reviews, hormone-related approaches are included alongside pharmacologic therapies for women at elevated fracture risk. The timing matters: earlier intervention, during the window of accelerated perimenopausal bone loss, is more effective than later. (De Villiers, 2023; LeBoff et al., 2022; Becheva & Taneva, 2020)

2. Strength Training and Weight-Bearing Exercise for Bone Density

Bone responds to mechanical load. When you stress bone through impact and resistance, osteoblasts activate and new bone is deposited. This is not optional for menopausal women. It is medicine.

Resistance training with progressive load, weight-bearing cardiovascular exercise, and impact activities like hopping and jumping all stimulate bone formation. The combination of exercise and adequate nutrition is more effective than either alone.

What the Research Shows

Exercise is one of the most consistently supported interventions in osteoporosis prevention. It stimulates bone formation, increases bone mineral density, improves strength and balance, and lowers fall and fracture risk. The Exercise and Sports Science Australia position statement specifically recommends progressive resistance training and impact exercise for bone health in postmenopausal women. (LeBoff et al., 2022; Beck et al., 2017; Chen et al., 2019; Papadopoulou et al., 2021)

3. Why Protein Intake Matters for Bone Health

Protein is structural. Roughly one-third of bone by weight is protein matrix, primarily collagen. Without adequate protein, bone cannot be properly mineralized or repaired. The data from the Women’s Health Initiative and other cohorts consistently shows that higher protein intake is associated with better bone density and lower fracture risk, particularly when combined with resistance training.

The target: 1.3 to 1.6 grams of protein per kilogram of ideal body weight per day. Most women are getting far less than this. You can track it easily with a nutrition app. It is worth knowing your number.

What the Research Shows

Higher protein intake, when paired with adequate calcium, is associated with lower fracture risk across multiple study populations. Protein supports both bone matrix and the muscle mass that protects against falls. The combination of protein-adequate nutrition and resistance training is consistently more effective for bone protection than either intervention alone. (Chen et al., 2019; Rizzoli & Chevalley, 2024; Tański et al., 2021; Papadopoulou et al., 2021)

4. Calcium, Vitamin D, and Vitamin K2 for Bone Strength

Calcium is the primary mineral in bone. Vitamin D is required for calcium absorption. Without adequate vitamin D, you can consume all the calcium you want and still be deficient where it counts. The combination of calcium and vitamin D supplementation improves bone mineral density and reduces hip fracture risk in postmenopausal women.

Vitamin D at 4,000 IU per day, taken with Vitamin K2 (which directs calcium into bone rather than soft tissue), is a reasonable supplementation strategy for most women. Food-first is always the goal, but supplementation fills the gap when dietary sources fall short.

What the Research Shows

Combined calcium and vitamin D supplementation is essential for bone mineralization. This combination improves BMD and reduces hip fracture rates in postmenopausal women when used consistently. Vitamin K2 co-supplementation is an area of growing interest for optimizing calcium metabolism. (LeBoff et al., 2022; Rizzoli & Chevalley, 2024; Anam & Insogna, 2021; Tański et al., 2021)

5. When Women Should Get a Bone Density (DEXA) Scan

Most guidelines say women should start bone density screening at 65. I believe this is too late for many women, and the research increasingly supports earlier assessment. If you are perimenopausal, have a family history of fracture, have had early or surgical menopause, have used corticosteroids, or smoke, you should be asking for a DEXA scan now.

A DEXA scan is quick, painless, and uses very low radiation. It gives you your T-score (how your bone density compares to a young adult reference) and your Z-score (how it compares to women your age). It is also used with the FRAX tool, which calculates your 10-year fracture probability based on bone density combined with other risk factors.

Knowing your baseline changes everything. You cannot optimize what you are not measuring.

What the Research Shows

DXA scans and fracture risk assessment tools like FRAX are the clinical standard for identifying women who need intensive prevention or pharmacologic intervention. Early assessment, particularly in women with known risk factors, allows for timely intervention during the window where lifestyle changes and MHT are most effective. (LeBoff et al., 2022; Anam & Insogna, 2021; Abdullah et al., 2023)

6. The Best Diet Pattern for Bone Health

Beyond protein and fiber, the overall quality of your diet matters for bone health. Mediterranean-style eating patterns, rich in fruits, vegetables, whole grains, healthy fats, and lean protein, are associated with lower fracture risk. Smoking accelerates bone loss. High alcohol intake does the same. These are not small effects.

What the Research Shows

Mediterranean-style diet patterns are associated with lower fracture risk, likely through a combination of anti-inflammatory micronutrients, fiber, and favorable effects on the gut microbiome. Smoking cessation and limiting alcohol are consistently supported as bone-protective strategies across all major guidelines. (Rizzoli & Chevalley, 2024; Tański et al., 2021; Zhu & Prince, 2015; LeBoff et al., 2022)

7. When Osteoporosis Medications Are Appropriate

For women with osteoporosis (T-score below -2.5) or osteopenia with high fracture risk, lifestyle changes alone may not be sufficient. There is a well-established pharmacologic toolkit. Antiresorptive agents like bisphosphonates and denosumab reduce bone breakdown. Anabolic agents like teriparatide, abaloparatide, and romosozumab actually build new bone. For women at highest fracture risk, anabolic agents have been shown to outperform antiresorptives in preventing vertebral and other fractures.

This is a shared decision-making conversation between you and your physician. What matters is that the conversation happens, and that it is grounded in your actual bone density data, not a best guess at 65.

Your Menopause Bone Health Action Plan

• Ask for a DEXA scan now if you are perimenopausal, have risk factors, or have never had one. Do not wait for 65.

• Hit your protein target: 1.3 to 1.6 grams per kg of ideal body weight, every day. Track it for a week so you know where you actually stand.

• Lift heavy things three days a week. Progressive resistance training is non-negotiable for bone health. Add hopping, jumping, or a weighted vest for additional impact stimulus.

• Supplement strategically: Vitamin D 4,000 IU daily with Vitamin K2. Calcium from food first, supplementation as needed.

• Discuss MHT with a menopause-informed provider. If you are in the perimenopausal window, this is also the window where bone protection through hormone therapy is most effective.

• Eat like your bones depend on it, because they do: anti-inflammatory, Mediterranean-leaning, high fiber, low added sugar. Stop smoking. Limit alcohol.

The Bottom Line: Osteoporosis Prevention Starts in Perimenopause

Osteoporosis is not an inevitable consequence of aging. It is a preventable consequence of unaddressed bone loss, accelerated by estrogen withdrawal, compounded by inadequate nutrition and inactivity, and diagnosed too late because we wait for fractures to tell us something is wrong.

You have a window right now. The perimenopause and early postmenopause years are when the tools work best. Exercise, protein, vitamin D, and hormone therapy during this period can protect bone density in a way that no intervention at 70 can fully replicate.

This is not about vanity. It is not about weight. It is about being able to pick up your grandchildren, walk without fear, and live the second half of your life with your skeleton intact.

Start now. Your future self will thank you.

Questions Every Woman Should Ask About Bone Density

1. “Should I have a DEXA scan now, given my menopausal status and risk factors?”

2. “Can you calculate my FRAX score so I understand my 10-year fracture probability?”

3. “Would I be a candidate for MHT, and would it help protect my bone density at this stage?”

4. “Am I getting enough protein and vitamin D based on my current diet and labs?”

5. “At what T-score would you consider pharmacologic intervention for me?”

Coming in Post 4:

Sarcopenia and Menopause: Why Muscle Loss Begins in Your 40s
Most women blame menopause for weight gain. But the real story is more specific and more serious: the loss of muscle mass that begins in your 40s, accelerates with estrogen withdrawal, and sets the stage for frailty, metabolic disease, and disability. Post 4 covers the sarcopenia crisis hiding inside the “normal aging” conversation, and exactly what to do about it.

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

If you ask most women what menopause causes, they will say hot flashes. If you ask most physicians what to treat in a menopausal patient, many will say vasomotor symptoms. And if you look at the STRAW staging system we discussed in Post 1, you will find that hot flashes and menstrual irregularity are essentially the only symptoms the framework bothers to mention.

This framing is not just incomplete. It is misleading in a way that has caused real harm to real women for decades.

Menopause is not a reproductive event with some uncomfortable side effects. It is a whole-body hormonal transition with consequences that reach into virtually every organ system in the human body. To understand why, you need to understand one foundational fact of female physiology.

Estrogen receptors are everywhere.

The question medicine has been slow to answer fully. When we ask what is affected by estrogen deprivation, the honest answer is: almost everything.

Why Estrogen Affects Nearly Every Organ System

Estrogen does not work by traveling to one location and doing one job. It works by binding to receptors that are distributed throughout the body, and when it binds, it activates gene expression, cellular function, and physiological processes specific to that tissue. Remove the estrogen, and you disrupt all of those processes simultaneously.

There are two primary estrogen receptors, ER-alpha and ER-beta, with distinct distributions across tissues. More recently, researchers have identified a third pathway through a receptor called GPER, the G protein-coupled estrogen receptor, which has expanded our understanding of just how broadly estrogen exerts its influence.

SOURCE: Prossnitz ER, Barton M. The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nature Reviews Endocrinology, 2023.

What you are looking at is a map of where estrogen’s influence reaches via the GPER pathway alone: the brain, the cardiovascular system, the immune system, the kidneys, the liver, the gastrointestinal tract, bone, and more. This is one receptor pathway. The full picture is broader still.

What this diagram tells us, and what the research literature confirms, is that estrogen is not a reproductive hormone that happens to cause some inconvenient symptoms when it declines. It is a systemic regulatory hormone, deeply involved in the maintenance of nearly every major organ system. Its loss is not a cosmetic event. It is a physiological one with long-term health consequences that compound over time.

Rethinking Menopause as Sex Hormone Deprivation

I want to introduce you to a framework that I find far more useful than the traditional “menopausal symptoms” language: sex hormone deprivation syndrome.

This framing matters because it changes how we think about what is happening. When we say “menopausal symptoms,” we imply that a woman is experiencing discomfort related to a natural transition. When we say “sex hormone deprivation syndrome,” we are saying something more precise and more actionable: a woman’s body is being deprived of hormones it depends on for normal physiological function, and the symptoms she is experiencing are the documented consequences of that deprivation.

Sex hormone deprivation syndrome: a more clinically precise and actionable framework than the traditional “menopausal symptoms” language.

The distinction is not merely semantic. It shapes whether a clinician reaches for a treatment, a referral, or a dismissal. It shapes whether a woman feels entitled to ask for help or whether she leaves the office thinking she simply needs to cope better.

Symptoms of Estrogen Loss Go Far Beyond Hot Flashes

When we catalog the documented manifestations of sex hormone deprivation, the list is striking in its breadth. These are not rare or idiosyncratic reactions. These are reproducible, physiologically explainable consequences of estrogen loss, documented across the research literature.

The documented symptom spectrum of sex hormone deprivation syndrome. Hot flashes appear in this list. They are not the title of it.

Look at that list carefully. Hot flashes and night sweats are there. So are mental health changes, brain fog, sleep disturbances, joint pain, fatigue, gastrointestinal changes, tinnitus, vertigo, burning mouth, heart palpitations, electric shock sensations, frozen shoulder, new or worsening autoimmune conditions, and insulin resistance.

A woman who presents with joint pain, brain fog, and new-onset anxiety is describing a coherent clinical picture. It is the picture of a body losing its hormonal regulatory support. The fact that she still has her period does not make these symptoms less real or less hormonal. It makes them perimenopausal.

And yet, how many of these women are told they have fibromyalgia? How many are referred to rheumatology? How many are prescribed SSRIs for anxiety that is, at its root, estrogen-driven? How many spend years cycling through specialists while the underlying hormonal cause goes unaddressed?

Too many. The answer is too many.

What Estrogen Loss Does to the Brain, Heart, Bone, and Metabolism

Let me walk you through the major organ systems and what estrogen loss actually does to each of them. This is the conversation that should be happening in every primary care office when a woman in her 40s or early 50s walks through the door.

Estrogen and the Brain: Why Cognitive Changes Occur in Perimenopause

Estrogen has profound effects on neurological function. It supports glucose metabolism in the brain, promotes synaptic plasticity, modulates serotonin and dopamine pathways, and has neuroprotective properties that appear to reduce the risk of neurodegenerative disease. When estrogen declines, brain glucose metabolism drops, particularly in regions associated with memory and executive function. This is the physiological basis for the brain fog, word-finding difficulties, and memory lapses that so many women describe during perimenopause. It is not anxiety. It is not early dementia. It is a measurable metabolic change in the brain driven by hormone loss.

Cardiovascular Risk After Menopause: The Loss of Estrogen Protection

Before menopause, women have significantly lower rates of cardiovascular disease than men of the same age. After menopause, that advantage disappears. Estrogen promotes vasodilation, reduces inflammation in arterial walls, supports favorable lipid profiles, and helps maintain endothelial function. Its loss accelerates atherosclerosis and increases cardiovascular risk. The cardiovascular disease rate in postmenopausal women eventually equals and then surpasses that of men. This is not coincidence. It is biology.

Bone Density Loss Begins in Perimenopause, Not Old Age

Estrogen is a primary regulator of bone remodeling. It suppresses osteoclast activity, the cells that break bone down, while supporting osteoblast function, the cells that build it back up. When estrogen drops, bone resorption accelerates. The fastest rate of bone loss in a woman’s entire life occurs not in her 70s, but during the perimenopause. Women can lose up to 20% of their bone density in the five to seven years around the final menstrual period. Most of them do not know this is happening until a fracture tells them.

Estrogen, Muscle Mass, and the Early Drivers of Sarcopenia

Estrogen receptors are present throughout skeletal muscle tissue. Estrogen supports muscle protein synthesis, satellite cell function (the stem cells that repair muscle), mitochondrial efficiency, and the regulation of muscle lipid metabolism. When estrogen declines, muscle mass loss accelerates significantly. Women in primary ovarian insufficiency have four times the risk of low muscle mass compared to women who go through menopause at the typical age. This sets the stage for sarcopenia, frailty, and loss of functional independence decades later.

Why Menopause Changes Weight, Fat Distribution, and Insulin Sensitivity

Estrogen plays a direct role in insulin sensitivity, pancreatic beta cell function, hepatic glucose regulation, and the distribution of body fat. Its loss is associated with increased insulin resistance and a dramatic shift in where fat is stored. Premenopausally, roughly 8% of total body fat is visceral fat, the metabolically active, pro-inflammatory fat stored around the organs. Postmenopausally, that figure rises to approximately 23%. This visceral fat accumulation is not caused by overeating or inactivity alone. It is a hormonally driven redistribution, and it carries real cardiovascular and metabolic consequences.

Genitourinary Syndrome of Menopause Is Progressive Without Treatment

The vaginal epithelium, the urethra, and the bladder all contain estrogen receptors and depend on estrogen for normal function. As estrogen declines, the vaginal tissue thins, loses elasticity, and becomes less lubricated. The urethra and bladder lose some of their structural support. The result is the genitourinary syndrome of menopause (GSM): a constellation of symptoms including vaginal dryness, pain with intercourse, urinary urgency, recurrent urinary tract infections, and pelvic floor dysfunction. Unlike hot flashes, which often improve over time, GSM is progressive. It does not get better without treatment. It gets worse.

Collagen Loss, Joint Pain, and Tissue Changes Linked to Estrogen Decline

Estrogen stimulates collagen production, supports skin hydration, and promotes hair follicle health. Its decline is associated with accelerated collagen loss (women lose approximately 30% of skin collagen in the first five years after menopause), increased skin dryness and thinning, and changes in hair density and texture. Joint cartilage also contains estrogen receptors, which helps explain why joint pain and stiffness are so common during perimenopause, even in women who had no prior joint issues.

Menopause Symptoms Do Not Reflect the Underlying Health Risks

The most important clinical reframe: menopause is not just a symptom experience. The silent changes are where the long-term damage accumulates.

This is perhaps the most important point in this entire series, and it is the one that gets lost most often in clinical care.

A woman who has no hot flashes is not a woman who is sailing through menopause without consequence. She may be a woman who is quietly losing bone density. She may be a woman whose cardiovascular risk is rising without a symptom to signal it. She may be a woman whose insulin resistance is building, whose visceral fat is accumulating, whose muscle mass is declining, all without a hot flash in sight.

The symptom experience of menopause and the disease risk of menopause are not the same thing. A woman who feels fine is not necessarily a woman whose body is fine. This is why waiting for symptoms before having a clinical conversation about menopause is the wrong approach. By the time symptoms appear, the silent changes have often been underway for years.

The Two Most Geroprotective Organs in the Female Body

An emerging framework in longevity research with profound implications for how we approach menopause care.

Emerging research in female longevity has produced a striking observation: the ovary and skeletal muscle appear to be the most geroprotective organs in the female body. Geroprotective means protective against the processes of aging, and the evidence for both of these is compelling.

The ovary, through its hormonal output, has been shown to regulate aging across multiple organ systems simultaneously. Women who experience early menopause or POI, and who do not receive hormone therapy, have higher rates of cardiovascular disease, osteoporosis, cognitive decline, and all-cause mortality than women who go through menopause at the typical age. The ovary, while it is functioning, is doing far more than enabling reproduction. It is actively protecting the female body against age-related disease.

Skeletal muscle is similarly protective. Muscle mass is one of the strongest predictors of longevity and functional independence in aging women. It is a metabolically active tissue that regulates glucose disposal, reduces systemic inflammation, and provides the physical reserve that protects against falls, fractures, and disability. Estrogen loss accelerates muscle loss. This is why maintaining and building muscle during and after the menopausal transition is not optional. It is one of the most powerful longevity interventions available to women.

The Six Major Health Conditions Accelerated by Estrogen Loss

The Big Six: the major conditions driven or accelerated by estrogen loss. Each one gets its own post.

The rest of this series is going to go deep on each of the six major conditions that estrogen loss drives or accelerates: osteoporosis, sarcopenia, insulin resistance, visceral fat accumulation, dementia, and cardiovascular disease. For each one, we will look at the biology, the risk data, and most importantly, what we can actually do about it.

Because that is the point of all of this. Not to frighten you. Not to overwhelm you with a list of things that are going wrong in your body. But to give you the information you need to make informed decisions, to have informed conversations with your doctor, and to take the specific actions that the evidence tells us can genuinely change your trajectory.

You are not simply aging. You are navigating a hormonal transition with documented, addressable consequences. There is a difference. And knowing the difference changes everything.

Coming in Post 3: Osteoporosis Risk Begins Earlier Than Most Women Realize

The Silent Fracture
Half of all women will have an osteoporotic fracture in their lifetime. The fastest bone loss of a woman’s life happens during perimenopause, not in her 70s. And most women are diagnosed with osteoporosis only after a fracture tells them something is wrong. Post 3 covers what you need to know, and what you need to do, starting now.

Questions to Discuss With Your Clinician About Menopause and Long-Term Health

1. “Beyond hot flashes, what other symptoms could be related to estrogen changes?”

2. “Can we assess my cardiovascular risk in the context of my menopausal status?”

3. “Should I be screened for bone density or insulin resistance given where I am in my hormonal transition?”

4. “What are the silent changes I should be monitoring even if I feel fine?”

Mary Claire Haver, MD | Board-Certified OB-GYN | Certified Menopause Practitioner
Author of The New Menopause | The Pause Life | thepauselife.com

I am about to tell you something that might surprise you coming from a board-certified OB-GYN and certified menopause practitioner.

I got my own estrogen dosing wrong.

Not because I was careless. Not because I did not know the science. Because I made the same assumption that most clinicians make every single day: that if a woman’s symptoms are controlled, her estradiol levels must be adequate.

My transdermal estradiol patch was managing my vasomotor symptoms perfectly. No hot flashes. Good sleep. I felt well. I assumed I was protected.

Then I checked my levels.

My serum estradiol was consistently running at about half of what the research says is needed to protect bone. Half. My hot flashes were gone. My skeleton was not getting what it needed.

That was a wake-up call. And the more I dug into the data, the more I became convinced that checking estradiol levels is not optional. It is essential. Let me show you why.

The Bone Data: What Level Actually Protects You?

This is where most clinicians stop the conversation too early. They treat to symptoms. Hot flashes gone? Great. Done. However, the bone data presents an entirely different picture.

The Study of Osteoporotic Fractures, an important research project by Ettinger and his team published in The Journal of Clinical Endocrinology and Metabolism, discovered that postmenopausal women with serum estradiol levels below 5 pg/mL had much lower bone mineral density and a higher risk of fractures compared to women with higher levels. That finding has been replicated and refined over the past two decades.

Bagur and colleagues (2004) found that even modestly higher endogenous estradiol levels, above 10 pg/mL, were associated with 6 to 14% higher bone mineral density in young postmenopausal women compared to those with lower levels. Six to fourteen percent. That could be the difference between a bone that holds and a bone that fractures.

Rapuri and colleagues (2004) confirmed that endogenous serum estradiol levels and sex hormone binding globulin independently determined bone mineral density, bone remodeling rates, and even the response to estrogen treatment in elderly women. In other words, your baseline estradiol level affects whether your hormone therapy is actually doing what you think it is doing.

And then there is the study that shifted how I think about target levels. Jamka and colleagues (2021) assessed biochemical bone turnover markers in postmenopausal women and found that only women with estradiol levels at or above 25 pg/mL had balanced bone formation and resorption markers. Below that threshold, resorption outpaced formation. The bone was being broken down faster than it was being built, even if the woman felt fine.

More recently, Zhu and colleagues (2021) described an inverted U-shaped relationship between estradiol and bone mineral density. BMD (bone mineral density) increases with estradiol up to approximately 70 pg/mL, after which there is no additional benefit and potentially even harm.

In plain terms: the bone-protective sweet spot appears to be roughly 25 to 70 pg/mL. Below 10, you are in trouble. Between 10 and 25, you are losing ground slowly. Above 25, bone formation and resorption come into balance. Above 70, you are not gaining anything more.

Here is the question I want you to ask yourself. Do you know where your estradiol level is? Does your doctor?

Because you cannot feel bone loss. Osteoporosis is silent until it is not. A vertebral compression fracture, a hip fracture, those are not subtle. But the years of gradual loss that lead to them? You will not feel a thing. The only way to know if your estradiol is high enough to protect your skeleton is to measure it.

The Heart Data: Estradiol and Your Arteries

Bone is not the only organ system with an estradiol threshold. Your cardiovascular system has one too.

The ELITE trial (Early vs. Late Intervention Trial with Estradiol) was published in The New England Journal of Medicine in 2016, and it is one of the most important studies in menopausal medicine. Hodis and colleagues showed that oral estradiol therapy, started within 6 years of menopause, significantly slowed the progression of carotid artery intima-media thickness, which is a direct measure of subclinical atherosclerosis. Women who started the same therapy more than 10 years after menopause did not get the same benefit (Hodis et al., 2016).

This is the timing hypothesis in action. Estrogen protects arteries that are still healthy. It does not reverse damage that has already calcified.

Sriprasert and colleagues (2018) took this further in a secondary analysis of the ELITE data, demonstrating that the cardiovascular benefit was driven by the plasma estradiol levels achieved, not just the fact of taking therapy. Higher estradiol levels in early postmenopause correlated with slower atherosclerosis progression.

In 2024, He and colleagues published a cross-sectional study in Frontiers in Endocrinology that divided postmenopausal women into estradiol tertiles. Women in the lowest tertile (2.1 to 3.6 pg/mL) had the highest prevalence of abdominal aortic calcification. Women in the highest tertile (7.1 to 38.4 pg/mL) had the lowest. The gradient was clear: more estradiol, less vascular calcification (He et al., 2024).

This is not subtle. This is your aorta telling you what it needs.

The Metabolic Data: Cholesterol, Blood Sugar, Insulin

The REPLENISH trial gave us some of the cleanest data on estradiol levels and metabolic outcomes. Sriprasert and colleagues (2020) found that in early postmenopausal women, meaning within 6 years of menopause, higher serum estradiol was significantly associated with lower total cholesterol, lower LDL cholesterol, lower fasting glucose, and higher HDL cholesterol.

These are the four metabolic markers that drive cardiovascular disease risk. And they all moved in the right direction with higher estradiol.

Here is the part that should make every clinician pay attention: these metabolic benefits were not seen in women who started therapy more than 10 years after menopause. The window matters. And within that window, the level matters.

The triglyceride story adds an important nuance. Oral estrogen can raise triglycerides through first-pass liver metabolism. Transdermal estrogen has a more neutral effect on triglycerides (Nie et al., 2022; Tao et al., 2022). This is one reason I use a transdermal patch as my primary delivery. But when my transdermal levels were not reaching the bone-protective range, I added a small dose of oral estradiol at night. My LDL and ApoB decreased after that addition. The cardiovascular markers moved in the right direction because my estradiol finally reached a level that could engage the lipid-clearing mechanisms.

Estrogen increases LDL receptor expression on the liver. More LDL receptors mean more LDL particles pulled out of circulation. But this mechanism requires adequate circulating estradiol to activate. If your levels are high enough to stop your hot flashes but not high enough to upregulate LDL clearance, you are getting symptom relief without metabolic protection.

For insulin sensitivity, the data is equally compelling. Pereira and colleagues (2015) demonstrated that estradiol therapy in early postmenopausal women increased insulin-mediated glucose disposal. The same therapy in late postmenopause had neutral or even adverse effects. Timing and levels, together, determine whether estrogen helps or does not.

So Why Don’t Current Guidelines Recommend Checking Levels?

This is the question I get from clinicians. The standard teaching is that menopause hormone therapy should be dosed to symptoms. If hot flashes are controlled, the dose is right. If they are not, increase. Simple.

And I understand the logic. Hormone levels fluctuate. A single blood draw is a snapshot. Perimenopause especially is chaotic, with estradiol swinging wildly day to day. In that context, chasing a number can be misleading.

But here is where I part ways with the guideline.

The guidelines were written around symptom management. The data I just showed you is about disease prevention. Those are different goals, and they are different thresholds.

A woman’s hot flashes may resolve at a serum estradiol of 20 pg/mL. Her bone formation and resorption do not come into balance until 25 or above. Her LDL receptor upregulation may require even more. Her vasculature is getting less protection than she thinks.

I am not suggesting we chase numbers blindly. I am suggesting that when we have clear data linking specific estradiol ranges to bone protection, cardiovascular benefit, and metabolic improvement, it is irresponsible to never check whether our patients are reaching those ranges.

Especially when we know that transdermal absorption is variable. Skin thickness, blood flow, body composition, patch formulation, and ambient temperature, all of these affect how much estradiol gets through the skin. Some women absorb beautifully. Some absorb far less than expected. The only way to know is to measure.

What I Actually Do in Practice

I check a serum estradiol level on my patients who are on hormone therapy, typically after they have been on a stable dose for several weeks. I use the LC/MS (liquid chromatography/mass spectrometry) method because it is more accurate at the lower levels we see in menopause than the standard immunoassay.

I am looking for a level that is not just controlling symptoms but reaching the range the data says is protective: ideally 25 pg/mL and above for bone, recognizing that the optimal range for bone appears to extend up to about 70 pg/mL before the benefit plateaus.

If a woman’s symptoms are controlled but her level is below that range, I have a conversation with her about options. A dose increase. A change in delivery method. In addition, like I did with my own protocol, adding a small dose of oral estradiol to bridge the gap.

And then I recheck. Because this is not a one-and-done number. It is a tool for ongoing management.

I also pay attention to the downstream markers. Is her LDL improving? Is her ApoB coming down? Is her fasting insulin stable? Is her DEXA trending in the right direction? Estradiol is one piece of the puzzle. But it is a piece that connects to everything else.

The Uncomfortable Truth

Here is what I want every woman reading this to understand.

You can feel great and still not be protected.

That is not meant to scare you. It is meant to empower you. Because the solution is simple: ask for the test. A serum estradiol level costs about $48. It tells you whether the hormone therapy you are investing time, money, and trust in is actually reaching the levels your bones, your heart, and your metabolism need.

If it is, wonderful. Keep going.

If it is not, now you have information you can act on. A dose adjustment. A delivery change. A conversation with your clinician that is grounded in data, not just how you feel.

I checked my own levels and found I was running at half of the bone-protective range while feeling perfectly fine. I adjusted. My estradiol rose. My LDL and ApoB dropped. My bones are getting what they need now. But I would never have known to make that change if I had not measured.

Your body is trying to tell you what it needs. Estradiol levels are one way to listen.

Knowledge is not fear mongering. Knowledge is freedom.

What to Ask Your Doctor

If you are currently on menopausal hormone therapy, here is what I want you to bring to your next appointment:

“I would like a serum estradiol level checked using the LC/MS method. I want to know whether my current dose is reaching the levels the research associates with bone protection and cardiovascular benefit, not just symptom control.”

If your clinician is unfamiliar with the data, share this post. Share the references below. This is not fringe science. This is The New England Journal of Medicine. This is The Journal of Clinical Endocrinology and Metabolism. This is the evidence.

And if you want the full picture of what is happening during perimenopause, why your brain, bones, metabolism, and muscles are all changing at once, and what to do about it, The New Perimenopause comes out April 7.

References

Ahmed, F., Kamble, P., Hetty, S., Fanni, G., Vranic, M., Sarsenbayeva, A., Kristófi, R., Almby, K., Svensson, M., Pereira, M., and Eriksson, J. (2022). Role of Estrogen and Its Receptors in Adipose Tissue Glucose Metabolism in Pre- and Postmenopausal Women. The Journal of Clinical Endocrinology and Metabolism, 107, e1879-e1889.

Bagur, A., Oliveri, B., Mautalen, C., Belotti, M., Mastaglia, S., Yankelevich, D., Sayegh, F., and Royer, M. (2004). Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. Climacteric, 7, 181-188.

Cagnacci, A., Soldani, R., Carriero, P., Am, P., Fioretti, P., and Melis, G. (1992). Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 74(6), 1396-400.

Ettinger, B., Pressman, A., Sklarin, P., Bauer, D., Cauley, J., and Cummings, S. (1998). Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. The Journal of Clinical Endocrinology and Metabolism, 83(7), 2239-43.

Gupta, P., and Srivastava, P. (2016). Study of Cardiovascular Risk Factors Amongst Peri And Post Menopausal Women And Their Correlation With Serum Estradiol Levels. International Journal of Scientific Research, 5.

He, L., Li, X., Shen, E., and He, Y. (2024). Association between serum estradiol levels and abdominal aortic calcification in postmenopausal woman: a cross-sectional study. Frontiers in Endocrinology, 15.

Hodis, H., Mack, W., Henderson, V., Shoupe, D., Budoff, M., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., Stanczyk, F., Selzer, R., and Azen, S. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. The New England Journal of Medicine, 374(13), 1221-31.

Jamka, K., Adamczuk, P., Skowronska, A., Bojar, I., and Raszewski, G. (2021). Assessment of the effect of estradiol on biochemical bone turnover markers among postmenopausal women. Annals of Agricultural and Environmental Medicine, 28(2), 326-330.

Marková, I., Hüttl, M., Miklankova, D., Šedová, L., Šeda, O., and Malínská, H. (2024). The Effect of Ovariectomy and Estradiol Substitution on the Metabolic Parameters and Transcriptomic Profile of Adipose Tissue in a Prediabetic Model. Antioxidants, 13.

Mawi, M. (2016). Serum estradiol levels and bone mineral density in postmenopausal women. 29, 90-95.

Nie, G., Yang, X., Wang, Y., Liang, W., Li, X., Luo, Q., Yang, H., Liu, J., Wang, J., Guo, Q., Yu, Q., and Liang, X. (2022). The effects of menopause hormone therapy on lipid profile in postmenopausal women: a systematic review and meta-analysis. Frontiers in Pharmacology, 13.

Pereira, R., Casey, B., Swibas, T., Erickson, C., Wolfe, P., and Pelt, R. (2015). Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. The Journal of Clinical Endocrinology and Metabolism, 100(12), 4456-62.

Pornel, B., Chevallier, O., and Netelenbos, C. (2002). Oral 17-beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women. Menopause, 9, 171-178.

Rapuri, P., Gallagher, J., and Haynatzki, G. (2004). Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. The Journal of Clinical Endocrinology and Metabolism, 89(10), 4954-62.

Speksnijder, E., De Brauw, G., Malekzadeh, A., Bisschop, P., Stenvers, D., and Siegelaar, S. (2023). Effect of Postmenopausal Hormone Therapy on Glucose Regulation in Women With Type 1 or Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 46(10), 1866-1875.

Sriprasert, I., Hodis, H., Bernick, B., Mirkin, S., and Mack, W. (2020). Effects of estradiol dose and serum estradiol levels on metabolic measures in early and late postmenopausal women in the REPLENISH trial. Journal of Women’s Health, 29, 1052-1058.

Sriprasert, I., Hodis, H., Karim, R., Stanczyk, F., Shoupe, D., Henderson, V., and Mack, W. (2018). Differential effect of plasma estradiol on subclinical atherosclerosis progression in early vs late postmenopause. The Journal of Clinical Endocrinology and Metabolism, 104, 293-300.

Tao, W., Cai, X., Masri, M., Găman, M., Prabahar, K., Baradwan, S., and Mao, P. (2022). The effect of transdermal 17-beta-estradiol combined with norethisterone acetate treatment on the lipid profile in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials. Steroids, 185.

Zhu, Z., Zhao, J., Fang, Y., and Hua, R. (2021). Association between serum estradiol level, sex hormone binding globulin level, and bone mineral density in middle-aged postmenopausal women. Journal of Orthopaedic Surgery and Research, 16.